# EDGAR Filing Document

**Accession Number:** 0001939965
**File Stem:** 0001213900-23-006509
**Filing Date:** 2023-2
**Character Count:** 247796
**Document Hash:** 4eb5393122e743c870debeee522cb49d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-006509.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0001213900-23-006509

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 6

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230131

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Brera Holdings PLC
- **CENTRAL INDEX KEY:** 0001939965
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-AMUSEMENT & RECREATION SERVICES [7900]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41606
- **FILM NUMBER:** 23574452

**BUSINESS ADDRESS:**
- **STREET 1:** IFSC, 25-28 NORTH WALL QUAY
- **STREET 2:** DUBLIN 1
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** D01 H104
- **BUSINESS PHONE:** 949-233-7869

**MAIL ADDRESS:**
- **STREET 1:** IFSC, 25-28 NORTH WALL QUAY
- **STREET 2:** DUBLIN 1
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** D01 H104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brera Holdings Ltd
- **DATE OF NAME CHANGE:** 20220726

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

For the month of January 2023

Commission File Number: 001-41606

**BRERA HOLDING PLC**

(Exact name of registrant as specified in its charter)

**Connaught House, 5th Floor**

**One Burlington Road**

**Dublin 4**

**D04 C5Y6**

**Ireland**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**Entry into a Material Definitive Agreement.**

On January 26, 2023, Brera Holdings PLC (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Revere Securities, LLC, as representative of the underwriters named on Schedule 1 thereto (the "Representative"), relating to the Company's initial public offering (the "Offering") of 1,500,000 Class B Ordinary Shares (the "Shares") of the Company, nominal value $0.005 per share (the "Class B Ordinary Shares"), at an Offering price of $5.00 per share (the "Offering Price"). Pursuant to the Underwriting Agreement, in exchange for the Representative's firm commitment to purchase the Shares, the Company agreed to sell the Shares to the Representative at a purchase price of $4.65 (93% of the public offering price per share). The Company also granted the Representative a 45-day over-allotment option to purchase up to an additional 225,000 Class B Ordinary Shares at the Offering Price, representing fifteen percent (15%) of the Class B Ordinary Shares sold in the Offering, from the Company, less underwriting discounts and commissions and a non-accountable expense allowance.

The Shares commenced trading on the Nasdaq Capital Market under the symbol "BREA." The closing of the Offering took place on January 31, 2023. After deducting underwriting discounts and commissions and non-accountable expense allowance, the Company received net proceeds of approximately $6,900,000.

The Company also issued the Representative a warrant to purchase up to 105,000 Class B Ordinary Shares (7% of the Class B Ordinary Shares sold in the Offering) (the "Representative's Warrants"). The Representative's Warrants are exercisable at any time from July 26, 2023 to July 26, 2028 for $5.00 per share (100% of the offering price per Class B Ordinary Share). The Representative's Warrants contain customary anti-dilution provisions for stock dividends, splits, mergers, and any future issuance of ordinary shares or ordinary shares equivalents at prices (or with exercise and/or conversion prices) below the exercise price. The Representative's Warrant also contains piggyback registration rights in compliance with FINRA Rule 5110.

The Shares were offered and sold and the Representative's Warrant was issued pursuant to the Company's Registration Statement on Form F-1 (File No. 333-268187), as amended (the "Registration Statement"), initially filed with the Securities and Exchange Commission (the "Commission") on November 4, 2022, and declared effective by the Commission on January 26, 2023, and the final prospectus filed with the Commission on January 30, 2023 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the "Securities Act"). The Shares, Representative's Warrant and the Class B Ordinary Shares underlying the Representative's Warrant were registered as a part of the Registration Statement. The Company intends to use the net proceeds from the Offering to purchase acquisition or management rights of football clubs, although the Company does not currently have any definitive plans or commitments for any such acquisitions or investments; continued investment in social impact football; sales and marketing; and working capital and general corporate purposes.

The Underwriting Agreement contained customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

The Company's officers, directors, and certain stockholders who, prior to the initial public offering, held Class B Ordinary Shares or the Company's Class A Ordinary Shares, nominal value $0.005 per share (together with the Class B Ordinary Shares, "Ordinary Shares"), have agreed, subject to certain exceptions, not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any Ordinary Shares or other securities convertible into or exercisable or exchangeable for Ordinary Shares for a period of 12 months without the prior written consent of the Representative.

The Underwriting Agreement and the Representative's Warrant issued to the Representative are filed as Exhibits 1.1 and 4.1, respectively, to this Current Report on Form 6-K (this "Current Report"), and the description of the material terms of the Underwriting Agreement and the Representative's Warrant are qualified in their entirety by reference to such exhibits.

**Other Events.**

On January 27, 2023, the Company issued a press release announcing the pricing of the Offering. On January 30, 2023, the Company issued a press release announcing its acquisition strategy. On January 31, 2023, the Company issued a press release announcing the closing of the Offering. Copies of these press releases are attached hereto as Exhibits 99.1, 99.2, and 99.3, respectively.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1 | [Underwriting Agreement, dated as of January 26, 2023, by and between Brera Holdings PLC and Revere Securities, LLC (as representative of the underwriters named therein)](ea172482ex1-1_brerahold.htm) |
| 4.1 | [Representative's Warrant, dated as of January 31, 2023](ea172482ex4-1_brerahold.htm) |
| 99.1 | [Press Release dated January 27, 2023](ea172482ex99-1_brerahold.htm) |
| 99.2 | [Press Release dated January 30, 2023](ea172482ex99-2_brerahold.htm) |
| 99.3 | [Press Release dated January 31, 2023](ea172482ex99-3_brerahold.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 31, 2023 | **BRERA HOLDINGS PLC** | **BRERA HOLDINGS PLC** |
|  | By: | /s/ Sergio Carlo Scalpelli |
|  |  | Sergio Carlo Scalpelli |
|  |  | Chief Executive Officer |

---

## Exhibit 1.1

**Exhibit 1.1**

**UNDERWRITING AGREEMENT**

January 26, 2023

Revere Securities, LLC

*The representative of the* 

*Underwriters listed on Schedule 1 hereto.* 

650 Fifth Ave., 35<sup>th</sup> Floor<br> New York, NY 10019

Ladies and Gentlemen:

The undersigned, Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the ***"Company"***), hereby confirms its agreement (this ***"Agreement"***) with Revere Securities, LLC together with its subsidiaries and affiliates (collectively ***"Revere,"*** hereinafter referred to as ***"you"*** or the ***"Representative"***) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the ***"Underwriters"*** or, individually, an ***"Underwriter"***) as follows:

 

**1.** **Purchase and Sale of Shares.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. <u>Firm Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1.1. *<u>Nature and Purchase of Firm Shares</u>* .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) On the basis of the representations and warranties herein contained, but subject to the terms and conditions
herein set forth, the Company agrees to issue in the aggregate 1,500,000 Class B Ordinary Shares of the Company, par value $0.005 per
share (the  ***"Class B Shares"***), and each Underwriter agrees to purchase by way of subscription, severally and
not jointly, at the Closing, an aggregate of 1,500,000 Class B Shares ( ***"Firm Shares"***). The offering and subscription
of the Firm Shares are herein referred to as the  ***"Offering."*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Firm Shares are to be offered together to the public at the offering price per one Firm Share as set
forth on Schedule 2 hereto (the  ***"Purchase Price"***). The Underwriters, severally and not jointly, agree to purchase
by way of subscription from the Company the number of Firm Shares set forth opposite their respective names on Schedule 1 attached hereto
and made a part hereof at the purchase price for one Firm Share of $4.65 (or 93% of the Purchase Price).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1.2. *<u>Firm Shares Payment and Delivery</u>* .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Delivery and payment for the Firm Shares shall be made no later than 1:00 p.m., Eastern time, on the second
(2<sup>nd</sup>) Business Day following the effective date (the  ***"Effective Date"***) of the Registration Statement
(as defined in <u>Section 2.1</u> below) (or the third (3<sup>rd</sup>) Business Day following the Effective Date if the Registration
Statement is declared effective after 4:01 p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representative and
the Company, at the offices of Carmel, Milazzo & Feil LLP, 55 West 39<sup>th</sup> Street, 18<sup>th</sup> Floor, New York, NY 10018
( ***"Representative's Counsel"***), or at such other place (or remotely by facsimile or other electronic transmission)
as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment for the Firm Shares are called
the  ***"Closing Date."*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Payment for the Firm Shares shall be made on the Closing Date by wire transfer in U.S. dollars (same day)
funds, payable to the order of the Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters)
representing the Firm Shares (or through the facilities of the Depository Trust Company ( ***"DTC"***)) for the account
of the Underwriters. The Firm Shares shall be registered in such name or names and in such authorized denominations as the Representative
may request in writing prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender
of payment by the Representative for all of the Firm Shares. The term  ***"Business Day"*** means any day other than
a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York,
New York.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2. <u>Over-allotment Option</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.1. *<u>Option Shares</u>* . For the purposes of covering any over-allotments in connection with the subscription
of the Firm Shares, the Company hereby grants to the Underwriters an option (the  ***"Over-allotment Option"***) to
purchase by way of subscription, in the aggregate, up to 225,000 additional Class B Shares (the  ***"Option Shares,"*** and along with the Firm Shares, the  ***"Shares"***), representing fifteen percent (15%) of the Firm Shares issued
in the offering, from the Company. The purchase price to be paid per Option Share shall be equal to the price per Option Share set forth
in Schedule 2. The Shares shall be issued directly by the Company and shall have the rights and privileges described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus referred to below. The offering and sale of the Shares are herein referred
to as the  ***"Offering."*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.2. *<u>Exercise of Option</u>* . The Over-allotment Option granted pursuant to <u>Section 1.2</u> hereof may be exercised by the Representative as to all (at any time) or any part (from time to time) of the Option Shares within forty-five
(45) days after the Effective Date. The Underwriters shall not be under any obligation to purchase by way of subscription any of the Option
Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of
written notice to the Company from the Representative, setting forth the number of the Option Shares to be purchased by way of subscription
and the date and time for delivery of and payment for the Option Shares (the  ***"Option Closing Date"***), which shall
not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and
the Representative, at the offices of Representative's Counsel or at such other place (including remotely by facsimile or other
electronic transmissions) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Shares
do not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option
with respect to all or any portion of the Option Shares subject to the terms and conditions set forth herein, (i) the Company shall become
obligated to issue to the Underwriters the number of the Option Shares specified in such notice and (ii) each of the Underwriters, acting
severally and not jointly, shall purchase by way of subscription that portion of the total number of the Option Shares then being purchased
as set forth in Schedule 1 opposite the name of such Underwriter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.3. *<u>Payment and Delivery</u>* . Payment for the Option Shares shall be made on the Option Closing
Date by wire transfer in U.S. dollars (same day) funds, payable to the order of the Company upon delivery to you of certificates (in form
and substance satisfactory to the Underwriters) representing the Option Shares (or through the facilities of DTC or via DWAC transfer)
for the account of the Underwriters. The Option Shares shall be registered in such name or names and in such authorized denominations
as the Representative may request in writing prior to the Option Closing Date. The Company shall not be obligated to issue or deliver
the Option Shares except upon tender of payment by the Representative for applicable Option Shares *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3. <u>Representative's Warrants</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3.1. *<u>Purchase Warrants</u>* . The Company hereby agrees to issue and sell to the Representative (and/or
its designees) on the Closing Date ( ***"Representative's Warrants"***) five-year warrants for the purchase of
a number of the Shares equal to seven percent (7.0%) of the number of the sum of the Firm Shares and Option Shares, if any, issued in
the Offering (the  ***"Representative Warrant Shares"***), pursuant to a warrant in the form attached hereto as Exhibit
A, at an initial exercise price of $5.00 (or 100% of the public offering price per Share). The Representative's Warrants and the
Representative Warrant Shares are hereinafter collectively referred to together as the  ***"Representative's Securities."*** The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the
Representative's Warrants and the Representative Warrant Shares during the one hundred eighty (180) day period after the Effective
Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative's
Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result
in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to
anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) an officer, partner, registered person
or affiliate of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing
lock-up restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3.2. *<u>Delivery</u>* . Delivery of the Representative's Warrants shall be made on the Closing Date
and shall be issued in the name or names and in such authorized denominations as the Representative may request.

**2.** **Representations and Warranties of the Company.** The Company
represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date and as of the Option
Closing Date, if any, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. <u>Filing of Registration Statement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1. *<u>Pursuant to the Securities Act</u>* . The Company has filed with the U.S. Securities and Exchange
Commission (the  ***"Commission"***) a registration statement, and an amendment or amendments thereto, on Form F-1
(File No. 333-268187), including any related prospectus or prospectuses, for the registration of the Shares and the Representative's
Securities under the Securities Act of 1933, as amended (the  ***"Securities Act"***), which registration statement
and amendment or amendments have been prepared by the Company in all material respects in conformity with the requirements of the Securities
Act and the rules and regulations of the Commission under the Securities Act (the  ***"Securities Act Regulations"***)
and will contain all material statements that are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations. Except as the context may otherwise require, such registration statement, as amended, on file with the Commission at
the time the registration statement became effective (including the Preliminary Prospectus included in the registration statement, financial
statements, schedules, exhibits and all other documents filed as a part thereof and all information deemed to be a part thereof as of
the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act Regulations (the  ***"Rule 430A Information"***)),
is referred to herein as the  ***"Registration Statement."*** If the Company files any registration statement pursuant
to Rule 462(b) of the Securities Act Regulations, then after such filing, the term  ***"Registration Statement"*** shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the
Commission on the date hereof.

Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a ***"Preliminary Prospectus."*** The Preliminary Prospectus, subject to completion, dated January 10, 2023, that was included in the Registration Statement immediately prior to the Applicable Time is hereinafter called the ***"Pricing Prospectus."*** The final prospectus in the form first furnished to the Underwriters for use in the Offering is hereinafter called the ***"Prospectus."*** Any reference to the ***"most recent Preliminary Prospectus"*** shall be deemed to refer to the latest Preliminary Prospectus included in the Registration Statement.

***"Applicable Time"*** means 5:00 p.m., Eastern time, on the date of this Agreement.

***"Issuer Free Writing Prospectus"*** means any "issuer free writing prospectus," as defined in Rule 433 of the Securities Act Regulations (***"Rule 433"***), including without limitation any "free writing prospectus" (as defined in Rule 405 of the Securities Act Regulations) relating to the Shares that is (i) required to be filed with the Commission by the Company, (ii) a "road show that is a written communication" within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Shares or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g).

***"Issuer General Use Free Writing Prospectus"*** means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a "bona fide electronic road show," as defined in Rule 433 (the ***"Bona Fide Electronic Road Show"***)), as evidenced by its being specified in Schedule 3 hereto.

***"Issuer Limited Use Free Writing Prospectus"*** means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.

***"Pricing Disclosure Package"*** means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing Prospectus and the information included on Schedule 3 hereto, all considered together.

***"Securities"*** means the Firm Shares, Option Shares, Representative's Warrants and Representative Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. <u>Pursuant to the Exchange Act</u>. The Company has filed with the Commission a Form 8-A (File No: 001-41606)
providing for the registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the  ***"Exchange Act"***), of the Class B Shares. The registration of the Class B Shares under the Exchange Act has become effective on or prior
to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the
Class B Shares under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating
such registration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. <u>Share Exchange Listing</u> *.* The Shares and the Representative Warrant Shares have been approved
for listing on the Nasdaq Capital Market (the  ***"Exchange"***), and the Company has taken no action designed to,
or likely to have the effect of, delisting of the Shares or the Representative Warrants Shares from the Exchange, nor has the Company
received any written notification that the Exchange is contemplating terminating such listing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4. <u>No Stop Orders, etc</u> *.* Neither the Commission nor, to the Company's knowledge, any state
regulatory authority has issued any written order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus
or the Prospectus or has instituted or, to the Company's knowledge, threatened to institute, any proceedings with respect to such
an order. The Company has complied with each request (if any) from the Commission for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5. <u>Disclosures in Registration Statement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.1. *<u>Compliance with Securities Act and 10b-5 Representation</u>* .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective,
complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus,
including the prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto,
and the Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities
Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering
and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable
Time, at the Closing Date or at any Option Closing Date (if any), contained, contains or will contain an untrue statement of a material
fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Pricing Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing
Date (if any), did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer
Limited Use Free Writing Prospectus, if any, does not conflict with the information contained in the Registration Statement, any Preliminary
Prospectus, the Pricing Prospectus or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, if any, as supplemented
by and taken together with the Pricing Prospectus as of the Applicable Time, did not include an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading; *provided*, *however*, that this representation and warranty shall not apply to statements made in reliance
upon and in conformity with written information furnished to the Company in writing with respect to the Underwriters by the Representative
expressly for use in the Registration Statement, the Pricing Prospectus or the Prospectus or any amendment thereof or supplement thereto.
The parties acknowledge and agree that such information provided by or on behalf of any Underwriter consists solely of the information
in the table set forth in the first paragraph of the "Underwriting" section and the disclosure contained in the "Underwriting"
subsections "Discounts and Expenses," "Representative's Warrants," "Tail Rights," or "Electronic
Offer, Sale and Distribution of Ordinary Shares" of the Prospectus (the  ***"Underwriters' Information"***).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as
of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing
Date (if any), included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; *provided*, *however*, that this representation and warranty shall not apply to the Underwriters' Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.2. *<u>Disclosure of Agreements</u>* . The agreements and documents described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus conform in all material respects to the descriptions thereof contained therein and there
are no agreements or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement,
that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company
is a party or by which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, or (ii) is material to the Company's business, has been duly authorized and validly executed by the
Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company's knowledge,
the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors' rights generally, (y) as enforceability of any indemnification or contribution provision may
be limited under the U.S. federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other
forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor
may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company's
knowledge, any other party is in default thereunder and, to the Company's knowledge, no event has occurred that, with the lapse
of time or the giving of notice, or both, would constitute a default thereunder, except for any default or event which would not reasonably
be expected to result in a Material Adverse Change (as defined below). To the Company's knowledge, performance by the Company of
the material provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation,
judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its
assets or businesses (each, a  ***"Governmental Entity"***), including, without limitation, those relating to environmental
laws and regulations, except for any violation which would not reasonably be expected to result in a Material Adverse Change (as defined
below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.3. *<u>Prior Securities Transactions</u>* . During the past three (3) years from the date of this Agreement,
no securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling,
controlled by or under common control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package
and any Preliminary Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.4. *<u>Regulations</u>* . The disclosures in the Registration Statement, the Pricing Disclosure Package
and the Prospectus concerning the effects of U.S. federal, state, local and all foreign regulation on the Offering and the Company's
business as currently contemplated are correct in all material respects and no other such regulations are required to be disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus which are not so disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6. <u>Changes after Dates in Registration Statement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6.1. *<u>No Material Adverse Change</u>* . Since the respective dates as of which information is given
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i)
there has been no material adverse change in the financial position or results of operations of the Company or its Subsidiaries taken
as a whole, nor any change or development that, singularly or in the aggregate, would involve a material adverse change in or affecting
the condition (financial or otherwise), results of operations, business, or assets of the Company or its Subsidiaries taken as a whole
(a  ***"Material Adverse Change"***); (ii) there have been no material transactions entered into by the Company or
its Subsidiaries, other than as contemplated pursuant to this Agreement; and (iii) no officer or director of the Company has resigned
from any position with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6.2. *<u>Recent Securities Transactions, etc</u>* . Subsequent to the respective dates as of which information
is given in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or
contemplated herein or disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not:
(i) issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid
any dividend or made any other distribution on or in respect to its capital stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7. <u>Independent Accountants</u>. To the knowledge of the Company, TAAD LLP ( ***"Auditor"***),
whose report is filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is
an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company
Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g)
of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8. <u>Financial Statements, etc</u> *.* The financial statements, including the notes thereto and supporting
schedules, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present in all material
respects the financial position and the results of operations of the Company at the dates and for the periods to which they apply; and
such financial statements have been prepared in conformity with International Financial Reporting Standards ( ***"IFRS"***)
as issued by International Accounting Standards Board ( ***"IASB"***), consistently applied throughout the periods
involved); and any supporting schedules included in the Registration Statement present fairly in all material respects the information
required to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included
in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the Securities Act or the Securities Act Regulations.
The pro forma and pro forma as adjusted financial information and the related notes, if any, included in the Registration Statement, the
Pricing Disclosure Package and the Prospectus have been properly compiled and prepared in all material respects in accordance with the
applicable requirements of the Securities Act and the Securities Act Regulations and present fairly in all material respects the information
shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to
give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement, the Pricing
Disclosure Package or the Prospectus regarding  ***"non-GAAP financial measures"*** (as such term is defined by the
rules and regulations of the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities
Act, to the extent applicable. Each of the Registration Statement, the Pricing Disclosure Package and the Prospectus discloses all material
off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with
unconsolidated entities or other persons that may have a material current or future effect on the Company's financial condition,
changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of
revenues or expenses. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) neither
the Company nor any of its subsidiaries listed in Exhibit 21.1 to the Registration Statement (each, a  ***"Subsidiary"*** and, collectively, the  ***"Subsidiaries"***), has incurred any material liabilities or obligations, direct or contingent,
or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any
dividends or made any distribution of any kind with respect to its Class A Ordinary Shares, par value $0.005 per share (the  ***"Class A Shares"***), Class B Shares or other capital stock (c) there has not been any change in the capital of the Company or any
of its Subsidiaries, or, other than in the course of business, any grants under any stock compensation plan, and (d) there has not been
any Material Adverse Change in the Company's long-term or short-term debt. The Company represents that it has no direct or indirect
subsidiaries other than those listed in Exhibit 21.1 to the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9. <u>Authorized Capital; Options, etc</u>. The Company had, at the date or dates indicated in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth
therein. Based on the assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
will have on the Closing Date the adjusted capitalization set forth therein. Except as set forth in, or contemplated by, the Registration
Statement, the Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date
or at any Option Closing Date, there will be no options, warrants, or other rights to purchase or otherwise acquire any authorized, but
unissued Class A Shares or Class B Shares or any security convertible or exercisable into Class A Shares or Class B Shares, or any contracts
or commitments to issue or sell Class A Shares or Class B Shares or any such options, warrants, rights or convertible securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10. <u>Valid Issuance of Securities, etc</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10.1. *<u>Outstanding Securities</u>* . All issued and outstanding securities of the Company issued prior
to the transactions contemplated by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable;
the holders thereof have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such
holders; and none of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or
similar contractual rights granted by the Company. The Class A Shares, Class B Shares, preferred shares and any other securities outstanding
or to be outstanding upon consummation of the Offering conform in all material respects to all statements relating thereto contained in
the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding Class A Shares
and Class B Shares were at all relevant times either registered under the Securities Act and the applicable state securities or  ***"blue sky"*** laws or, based in part on the representations and warranties of the purchasers of such shares, exempt from such registration
requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10.2. *<u>Securities Sold Pursuant to this Agreement</u>* .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Shares have been duly authorized for issuance and sale and, when issued and paid for, will be validly
issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability by reason of being such
holders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) When issued, the Representative's Warrants will constitute valid and binding obligations of the
Company to issue and sell, upon exercise thereof and payment of the exercise price therefor, the number and type of securities of the
Company called for thereby in accordance with the terms thereof and the Representative's Warrants will be enforceable against the
Company in accordance with their terms; provided, however, that the enforceability thereof may be limited by bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium, and similar laws relating to or affecting creditors' rights generally and by general
principles of equity (regardless of whether such enforceability is considered a proceeding in equity or at law).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Shares and Representative's Warrants are not and will not be subject to the preemptive rights
of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required
to be taken for the authorization, issuance and sale of the Shares and Representative's Warrants has been duly and validly taken.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) The Representative Warrant Shares have been duly authorized and reserved for issuance by all necessary
corporate action on the part of the Company and when issued in accordance with such Representative's Warrants, such Representative
Warrant Shares will be validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) The Securities conform in all material respects to all statements with respect thereto contained in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11. <u>Registration Rights of Third Parties</u>. Except as set forth in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable
into securities of the Company have the right to require the Company to register any such securities of the Company under the Securities
Act or to include any such securities in a registration statement to be filed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12. <u>Validity and Binding Effect of Agreements</u> *.* This Agreement and the Representative's
Warrants have been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding
agreements of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors' rights generally; (ii) as enforceability
of any indemnification or contribution provision may be limited under the U.S. federal and state securities laws; and (iii) that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13. <u>No Conflicts, etc</u> *.* The execution, delivery and performance by the Company of this Agreement
and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by
the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both:
(i) result in a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result
in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to the terms of any agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions of
the Company's Constitution (as the same may be amended or restated from time to time, the  ***"Charter"***);
or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof;
except with respect to (i) and (iii) above for any such breach, conflict, violation, default, lien, charge or encumbrance that would not
reasonably be expected to result in, individually or in the aggregate, a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14. <u>No Defaults; Violations</u> *.* No material default exists in the due performance and observance
of any term, covenant or condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement,
or any other agreement or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which
the Company is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The
Company is not (i) in violation of any term or provision of its Charter, or (ii) in violation of any franchise, license, permit, applicable
law, rule, regulation, judgment or decree of any Governmental Entity, except in the cases of clause (ii) for such violations which would
not reasonably be expected to cause a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15. <u>Corporate Power; Licenses; Consents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15.1. *<u>Conduct of Business</u>* . Except as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company has all requisite corporate power and authority, and has all necessary authorizations, approvals,
orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof
to conduct its business purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except
for the absence of which would not reasonably be expected to result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15.2. *<u>Transactions Contemplated Herein</u>* . The Company has all corporate power and authority to enter
into this Agreement and to carry out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required
in connection therewith have been obtained. No consent, authorization or order of, and no filing with, any court, government agency, the
Exchange or other body is required for the valid issuance, sale and delivery of the Shares and the consummation of the transactions and
agreements contemplated by this Agreement and the delivery of the Representative's Warrants and as contemplated by the Registration
Statement, the Pricing Disclosure Package and the Prospectus, except with respect to applicable Securities Act Regulations, state securities
laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. ( ***"FINRA"***).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16. <u>D&O Questionnaires</u> *.* To the Company's knowledge, all information contained in the
questionnaires (the  ***"Questionnaires"***) completed by each of the Company's directors and officers immediately
prior to the Offering (the  ***"Insiders"***) as supplemented by all information concerning the Company's directors,
officers and principal shareholders as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as
well as in the Lock-Up Agreement (as defined in <u>Section 2.24</u> below), provided to the Underwriters, is true and correct in
all material respects and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires
to become materially inaccurate and incorrect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17. <u>Litigation; Governmental Proceedings</u> *.* There is no material action, suit, proceeding, inquiry,
arbitration, investigation, litigation or governmental proceeding pending or, to the Company's knowledge, threatened against, or
involving the Company or, to the Company's knowledge, any executive officer or director that is required to be disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus which has not been disclosed *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18. <u>Duly Organized; Good Standing</u> *.* The Company has been duly organized and is validly existing
as a corporation and is in good standing under the laws of its formation as of the date hereof, and is duly qualified to do business and
is in good standing in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification,
except where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material
Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19. <u>Subsidiaries</u>. All Subsidiaries of the Company are duly organized and in good standing under the
laws of the place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership
or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have a Material
Adverse Change. The Company's ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20. <u>Insurance</u> *.* The Company carries or is entitled to the benefits of insurance, (including,
without limitation, as to directors and officers insurance coverage), with, to the Company's knowledge, reputable insurers, in such
amounts and covering such risks which the Company believes are adequate, and all such insurance is in full force and effect. The Company
has no reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii)
to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and
at a cost that would not result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21. <u>Transactions Affecting Disclosure to FINRA</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21.1. *<u>Finder's Fees</u>* . Except as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder's,
consulting or origination fee by the Company or any Insider with respect to the sale of the Shares hereunder or any other arrangements,
agreements or understandings of the Company or, to the Company's knowledge, any of its shareholders that may affect the Underwriters'
compensation, as determined by FINRA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21.2. *<u>Payments within Six (6) Months</u>* . Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to:
(i) any person, as a finder's fee, consulting fee or otherwise, in consideration of such person raising capital for the Company
or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity
that has any direct or indirect affiliation or association with any FINRA member, within the six (6) months immediately prior to the original
filing of the Registration Statement, other than the payment to the Underwriters as provided hereunder in connection with the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21.3. *<u>Use of Proceeds</u>* . None of the net proceeds of the Offering will be paid by the Company to
any participating FINRA member or its affiliates, except as specifically authorized herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21.4. *<u>FINRA Affiliation</u>* . To the Company's knowledge, and except as may otherwise be disclosed
in FINRA questionnaires provided to the Representative's Counsel, there is no (i) officer or director of the Company, (ii) beneficial
owner of 5% or more of any class of the Company's securities or (iii) beneficial owner of the Company's unregistered equity
securities which were acquired during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate
or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21.5. *<u>Information</u>* . All information provided by the Company in its FINRA questionnaire to the Representative's
Counsel specifically for use by the Representative's Counsel in connection with its Public Offering System filings (and related
disclosure) with FINRA is true, correct and complete in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.22. <u>Foreign Corrupt Practices Act</u> *.* None of the Company and its Subsidiaries or, to the Company's
knowledge, any director, officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf
of the Company and its Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than
legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or
supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political
party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business
of the Company (or assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or
penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse
Change or (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The
Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply
in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.23. <u>Compliance with OFAC</u> *.* None of the Company and its Subsidiaries or, to the Company's
knowledge, any director, officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf
of the Company and its Subsidiaries, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of
the U.S. Department of the Treasury ( ***"OFAC"***), and the Company will not, directly or indirectly, use the proceeds
of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.24. <u>Money Laundering Laws</u>. The operations of the Company and its Subsidiaries are and have been conducted
at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the  ***"Money Laundering Laws"***); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect
to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.25. <u>Officers' Certificate</u> *.* Any certificate signed by any duly authorized officer of the
Company and delivered to you or to Representative's Counsel shall be deemed a representation and warranty by the Company to the
Underwriters as to the matters covered thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.26. <u>Lock-Up Agreements</u>. Schedule 5 hereto contains a complete and accurate list of the Company's
officers, directors and certain owners of record of the Company's outstanding Class B Shares (or securities convertible or exercisable
into Class B Shares, including, without limitation, any Class A Shares) (collectively, the  ***"Lock-Up Parties"***)
to deliver to the Representative an executed Lock-Up Agreement, in a form substantially similar to that attached hereto as Exhibit B (the  ***"Lock-Up Agreement"***), prior to the execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.27. <u>Related Party Transactions</u> *.* There are no business relationships or related party transactions
involving the Company or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus that have not been described as required by the Securities Act Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.28. <u>Board of Directors</u> *.* Upon the effectiveness of the Offering, the Board of Directors of the
Company will be comprised of the persons set forth under the heading of the Pricing Prospectus and the Prospectus captioned "Management."
The qualifications of the persons serving as board members and the overall composition of the board comply with the Exchange Act, the
Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the  ***"Sarbanes-Oxley Act"***)
applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the Board of Directors
of the Company qualifies as an "audit committee financial expert," as such term is defined under Regulation S-K and the listing
rules of the Exchange. In addition, at least a majority of the persons serving on the Board of Directors qualify as "independent,"
as defined under the listing rules of the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29. <u>Sarbanes-Oxley Compliance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29.1. *<u>Disclosure Controls</u>* . Except as disclosed in the Registration Statement, Pricing Disclosure
Package and the Prospectus, the Company has developed and currently maintains disclosure controls and procedures that will comply with
Rule 13a-15 or 15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure that all material information
concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company's
Exchange Act filings and other public disclosure documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29.2. *<u>Compliance</u>* . The Company is, or at the Applicable Time and on the Closing Date will be, in
material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs
and has taken reasonable steps to ensure the Company's future compliance (not later than the relevant statutory and regulatory deadlines
therefor) with all of the material provisions of the Sarbanes-Oxley Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.30. *<u>Accounting Controls</u>* . Except as disclosed in the Registration Statement, Pricing Disclosure
Package and the Prospectus, the Company maintains systems of "internal control over financial reporting" (as defined under
Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply in all material respects with the requirements of the Exchange
Act and have been designed by, or under the supervision of, its respective principal executive and principal financial officers, or persons
performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with IFRS, including, but not limited to, internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset
accountability; (iii) access to assets is permitted only in accordance with management's general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company is not aware of any material weaknesses in its internal control over financial reporting, and, if applicable, with respect
to such remedial actions disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company represents
that it has taken all remedial actions set forth in such disclosure. The Company's auditors and the Audit Committee of the Board
of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation
of internal controls over financial reporting which are known to the Company's management and that have adversely affected or are
reasonably likely to adversely affect the Company' ability to record, process, summarize and report financial information; and (ii)
any fraud known to the Company's management, whether or not material, that involves management or other employees who have a significant
role in the Company's internal controls over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.31. <u>No Investment Company Status</u>. The Company is not and, after giving effect to the Offering and the
application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will
not be, required to register as an  ***"investment company,"*** as defined in the Investment Company Act of 1940, as
amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.32. <u>No Labor Disputes</u> *.* No labor dispute with the employees of the Company or any of its Subsidiaries
exists or, to the knowledge of the Company, is imminent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.33. <u>Intellectual Property Rights</u>. The Company and each of its Subsidiaries owns or possesses or has
valid rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations,
copyrights, licenses, inventions, trade secrets and similar rights ( ***"Intellectual Property Rights"***) necessary
for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries
necessary for the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will
involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. Neither the Company
nor any of its Subsidiaries has received any written notice alleging any such infringement, fee or conflict with asserted Intellectual
Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse
Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual
Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding
or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of
any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other
claims in this <u>Section 2.32</u>, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property
Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been
adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company's
knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property
Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in
the aggregate, together with any other claims in this <u>Section 2.32</u>, reasonably be expected to result in a Material Adverse
Change; (D) there is no pending or, to the Company's knowledge, threatened action, suit, proceeding or claim by others that the
Company infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company
has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for
any such claim that would, individually or in the aggregate, together with any other claims in this <u>Section 2.32</u>, reasonably
be expected to result in a Material Adverse Change; and (E) to the Company's knowledge, no employee of the Company is in or has
ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment
agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former
employer where the basis of such violation relates to such employee's employment with the Company, or actions undertaken by the
employee while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse
Change. To the Company's knowledge, all material technical information developed by and belonging to the Company which has not been
patented has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with respect to the
Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, the Pricing
Disclosure Package and the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure Package and the
Prospectus contain in all material respects the same description of the matters set forth in the preceding sentence. None of the technology
employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company
or, to the Company's knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.34. <u>Taxes</u>. Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined)
required to be filed with local taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof,
except in any case in which the failure so to file would not reasonably be expected to cause a Material Adverse Change. Each of the Company
and its Subsidiaries has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed
on or assessed against the Company or such respective Subsidiary, except for any such taxes that are currently being contested in good
faith or as would not reasonably be expected to cause a Material Adverse Change. The provisions for taxes payable, if any, shown on the
financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not
disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to
the Underwriters, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns
or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns
or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term  ***"taxes"*** means all U.S. federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any
penalties, additions to tax or additional amounts with respect thereto. The term  ***"returns"*** means all returns,
declarations, reports, statements and other documents required to be filed in respect to taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.35. <u>ERISA Compliance</u> *.* The Company is not subject to the Employee Retirement Income Security
Act of 1974, as amended, or the regulations and published interpretations thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.36. <u>Compliance with Laws</u>. Except as otherwise disclosed in the Registration Statement, Pricing Disclosure
Package and Prospectus and as could not, individually or in the aggregate, be expected to result in a Material Adverse Change, each of
the Company and each Subsidiary: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to
the services provided by the Company ( ***"Applicable Laws"***), except as could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence
or notice from any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws ( ***"Authorizations"***);
(C) possesses all material Authorizations and such material Authorizations are valid and in full force and effect and are not in material
violation of any term of any such Authorizations; (D) has not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental authority or third
party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding that if brought would result in
a Material Adverse Change; (E) has not received written notice that any Governmental Authority has taken, is taking or intends to take
action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering
such action ; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects
on the date filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily,
initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert,
post-sale warning, or other notice or action relating to the alleged lack of safety of any product or any alleged product defect or violation
and, to the Company's knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.37. <u>Intentionally omitted</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.38. <u>Real Property</u> *.* Except as set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to
lease or otherwise use, all items of real or personal property which are material to the business of the Company and its Subsidiaries
taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or
in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made of such
property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries,
considered as one enterprise, and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received
any written notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary
under any such leases or subleases, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession
of the leased or subleased premises under any such lease or sublease, which would result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.39. <u>Contracts Affecting Capital</u>. There are no transactions, arrangements or other relationships between
and/or among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated
entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected
to materially affect the Company's or its Subsidiaries' liquidity or the availability of or requirements for their capital
resources required to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus which have not been described or incorporated by reference as required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.40. <u>Loans to Directors or Officers</u>. There are no outstanding loans, advances (except normal advances
for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the
benefit of any of the officers or directors of the Company, its Subsidiaries or any of their respective family members, except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.41. <u>Industry Data; Forward-Looking Statements</u> *.* The statistical and market-related data included
in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the
Company reasonably and in good faith believes are reliable and accurate or represent the Company's good faith estimates that are
made on the basis of data derived from such sources. No forward-looking statement (within the meaning of Section 27A of the Securities
Act and Section 21E of the Exchange Act) contained in the Prospectus has been made or reaffirmed without a reasonable basis or has
been disclosed other than in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.42. <u>Testing-the-Waters Communications</u>. The Company has not (i) alone engaged in any Testing-the-Waters
Communications and (ii) authorized anyone to engage in Testing-the-Waters Communications. The Company confirms that the Representative
has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written
Testing-the-Waters Communications other than those listed on Schedule 4 hereto.  ***"Written Testing-the-Waters Communication"*** means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act;  ***"Testing-the-Waters Communication"*** means any oral or written communication with potential investors undertaken in reliance on Section 5(d)
of the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.43. <u>Emerging Growth Company</u>. From the time of the initial confidential submission of the Registration
Statement to the Commission (or, if earlier, the first date on which the Company engaged directly in or through any Person authorized
to act on its behalf in any Testing-the Waters Communication) through the date hereof, the Company has been and is an "emerging
growth company," as defined in Section 2(a) of the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.44. <u>Electronic Road Show</u> *.* If applicable, the Company has made available a Bona Fide Electronic
Road Show in compliance with Rule 433(d)(8)(ii) of the Securities Act Regulations such that no filing of any  ***"*** road
show" (as defined in Rule 433(h) of the Securities Act Regulations) is required in connection with the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.45. <u>Margin Securities</u> *.* The Company owns no "margin securities" as that term is defined
in Regulation U of the Board of Governors of the Federal Reserve System (the  ***"Federal Reserve Board"***), and none
of the proceeds of the Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for
the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any
other purpose which might cause any of the Class A Shares to be considered a "purpose credit" within the meanings of Regulation
T, U or X of the Federal Reserve Board *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.46. <u>Dividends and Distributions</u>. Except as disclosed in the Pricing Disclosure Package, Registration
Statement and the Prospectus, no Subsidiary of the Company is currently prohibited or restricted, directly or indirectly, from paying
any dividends to the Company, from making any other distribution on such Subsidiary's capital stock, from repaying to the Company
any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary's property or assets to the
Company or any other Subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.47. <u>Lending Relationships</u>. Except as disclosed in the Pricing Disclosure Package, Registration Statement
and the Prospectus, the Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the
Underwriters and (ii) does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt
owed to any affiliate of the Underwriters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.48. <u>Foreign Private Issuer</u>. The Company is a "foreign private issuer" as defined in Rule
405 of the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.49. <u>Passive Foreign Investment Company Status</u>. Based on the Company's current estimates of its
gross income and the value of its gross assets (including goodwill) and the manner in which the Company conducts its business, the Company
was not a Passive Foreign Investment Company within the meaning of Section 1297 of the Code (a  ***"PFIC"***)
for the taxable year ended December 31, 2021 and does not expect that it will become a PFIC for the taxable year ending December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50. <u>Irish Legal Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.1. Subject to conducting the Offering as provided for in the section titled "Underwriting"
in the Preliminary Prospectus, the Company is not required to publish a prospectus in the Republic of Ireland ( ***"Ireland"***)
under Irish law with respect to the offer and sale of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.2. There are no proceedings that have been instituted in Ireland for the dissolution of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.3. Assuming that the Underwriters do not maintain a permanent establishment in Ireland, are not otherwise
subject to taxation in Ireland, or are exempt therefrom, the issuance, delivery and sale to the Underwriters of the Shares to be sold
by the Company hereunder are not subject to any tax imposed by Ireland or any political subdivision thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.4. Neither the Company nor any of its properties or assets has any immunity from the jurisdiction of any
court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise)
under the laws of Ireland.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.5. The Company has duly designated Cogency Global Inc. as its authorized agent to receive service of process
as set forth in <u>Section 9.6.2</u> below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.6. No stamp duty or similar tax or duty is payable under applicable laws or regulations of Ireland in connection
with the creation, issuance or delivery of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.7. Subject to the conditions, exceptions and qualifications set forth in the Registration Statement, and
the Preliminary Prospectus, a final and conclusive judgment against the Company for a definitive sum of money entered by any court in
the United States may be enforced by an Irish court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.50.8. The choice of the laws of the State of New York as the governing law of this Agreement is a valid choice
of law under the laws of Ireland.

**3.** **Covenants of the Company**. The Company covenants and agrees
as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1. <u>Amendments to Registration Statement</u> *.* The Company shall deliver to the Representative, prior
to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not
file any such amendment or supplement to which the Representative shall reasonably object in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2. <u>Federal Securities Laws</u> *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.1. *<u>Compliance</u>* . The Company, subject to <u>Section 3.2.2</u>, shall comply with the requirements
of Rule 430A of the Securities Act Regulations, and will notify the Representative promptly, and confirm the notice in writing, (i) when
any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall
have been filed; (ii) of the receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to
the Registration Statement or any amendment or supplement to the Prospectus or for additional information; (iv) of the issuance by the
Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order
preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Shares
and the Representative's Warrants for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings
for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration
Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the
Offering of the Shares and Representative's Warrants. The Company shall effect all filings required under Rule 424(b) of the Securities
Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take
such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received
for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use its reasonable
best efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting
thereof at the earliest possible moment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.2. *<u>Continued Compliance</u>* . The Company shall comply with the Securities Act, the Securities Act
Regulations, the Exchange Act and the Exchange Act Regulations so as to permit the completion of the distribution of the Shares as contemplated
in this Agreement and in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus
relating to the Shares is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations ( ***"Rule 172"***),
would be) required by the Securities Act to be delivered in connection with sales of the Shares, any event shall occur or condition shall
exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration
Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure
Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the
light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement
the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or
the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment
or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure
Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish
the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; *provided* that the Company shall not file or use any such amendment or supplement to which the Representative or Representative's
Counsel shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as
the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange
Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of
its intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration
of the Over-allotment Option specified in <u>Section 1.1.2(ii)</u> hereof and will furnish the Representative with copies of the
related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document
to which the Representative or counsel for the Underwriters shall reasonably object.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.3. *<u>Exchange Act Registration</u>* . Until three (3) years after the date of this Agreement, the Company
shall use its commercially reasonable efforts to maintain the registration of the Class B Shares under the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.4. *<u>Free Writing Prospectuses</u>* . The Company agrees that, unless it obtains the prior consent
of the Representative, it shall not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that
would otherwise constitute a "free writing prospectus," or a portion thereof, required to be filed by the Company with the
Commission or retained by the Company under Rule 433; *provided* that the Representative shall be deemed to have consented to each
Issuer General Use Free Writing Prospectus set forth in Schedule 3. The Company represents that it has treated or agrees that it will
treat each such free writing prospectus consented to, or deemed consented to, by the Underwriters as an "issuer free writing prospectus,"
as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including
timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would
conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.5. *<u>Testing-the-Waters Communications</u>* . If at any time following the distribution of any Written
Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters
Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company
shall promptly notify the Representative and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication
to eliminate or correct such untrue statement or omission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3. <u>Delivery to the Underwriters of Registration Statements</u>. The Company has delivered or made available
or shall deliver or make available to the Representative and Representative's Counsel, without charge, signed copies of the Registration
Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates
of experts, and upon request will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as
originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement
and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with
the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4. <u>Delivery to the Underwriters of Prospectuses</u> *.* The Company has delivered or made available
or will deliver or make available to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter
reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company
will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Shares is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended
or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the
Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to
the extent permitted by Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5. <u>Effectiveness and Events Requiring Notice to the Representative</u> *.* The Company shall use its
commercially reasonable efforts to cause the Registration Statement covering the issuance of the Class A Shares underlying the Representative's
Warrants to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative
immediately and confirm the notice in writing: (i) of the cessation of the effectiveness of the Registration Statement and any amendment
thereto; (ii) of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that
purpose; (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the shares
underlying the Representative's Warrants for offering or sale in any jurisdiction or of the initiation, or the threatening, of any
proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration
Statement or Prospectus; (v) of the receipt of any comments or request for any additional information from the Commission; and (vi) of
the happening of any event during the period described in this <u>Section 3.4</u> that, in the judgment of the Company, makes any
statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that requires
the making of any changes in (a) the Registration Statement in order to make the statements therein not misleading, or (b) in the Pricing
Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time,
the Company shall make every reasonable effort to obtain promptly the lifting of such order.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6. <u>Review of Financial Statements *.*</u> For a period of three (3) years after the date of this Agreement,
so long as the Company is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act, the
Company, at its expense, shall use its commercially reasonable efforts to cause its regularly engaged independent registered public accounting
firm to review (but not audit) the Company's financial statements for each of the three fiscal quarters immediately preceding the
announcement of any quarterly financial information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7. <u>Listing</u> *.* The Company shall use its commercially reasonable efforts to maintain the listing
of the Class A Shares and the Class A Shares underlying the Representative's Warrant on the Exchange for at least three (3) years
from the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8. <u>Payment of Expenses.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8.1. *<u>General Expenses Related to the Offering</u>* . The Company hereby agrees to pay on each of the
Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance
of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and communication expenses
relating to the registration of the Shares to be sold in the Offering (including the Over-allotment Option) with the Commission; (b) all
Public Filing System filing fees associated with the review of the Offering by FINRA; (c) all fees, expenses and disbursements relating
to the registration, qualification or exemption of the Shares under the securities laws of such foreign jurisdictions as the Representative
may reasonably designate; (d) all fees, expenses and disbursements relating to background checks of the Company's officers and directors
and other due diligence expenses; (e) the costs associated with receiving commemorative mementos and lucite tombstones; (f) fees and expenses
of the Representative's Counsel; (g) the Underwriters' due diligence expenses; and (h) the Underwriters' "road
show" expenses for the Offering, with all of the Underwriters' actual out-of-pocket expenses under subsections 3.8(d)-(h)
not to exceed $200,000. The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing Date
or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters; *provided*, *however*,
that in the event that the Offering is terminated, the Company agrees to reimburse the Underwriters pursuant to <u>Section 8.2</u> hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8.2. *<u>Non-Accountable Expense Allowance</u>* . The Company further agrees that, in addition to the expenses
payable pursuant to <u>Section 3.8</u>, on the Closing Date, it shall pay to the Representative, by deduction from the net proceeds
of the Offering contemplated herein, a non-accountable expense allowance equal to one percent (1.0%) of the gross proceeds received by
the Company from the sale of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9. <u>Application of Net Proceeds</u> *.* The Company shall apply the net proceeds from the Offering
received by it in a manner consistent with the application thereof described under the caption "Use of Proceeds" in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10. <u>Delivery of Earnings Statements to Security Holders</u>. The Company will timely file such reports
pursuant to the Exchange Act as are necessary in order to make generally available to its security holders as soon as practicable, an
earnings statement (which need not be certified by an independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities
Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11. <u>Stabilization</u> *.* Neither the Company nor, to its knowledge, any of its employees, directors
or shareholders has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12. <u>Internal Controls</u>. Except to the extent disclosed in the Registration Statement, Pricing Disclosure
Package and Prospectus, the Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances
that: (i) transactions are executed in accordance with management's general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets;
(iii) access to assets is permitted only in accordance with management's general or specific authorization; and (iv) the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13. <u>Accountants</u>. As of the date of this Agreement, the Company has retained an independent registered
public accounting firm reasonably acceptable to the Representative, and the Company shall continue to retain a nationally recognized independent
registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges
that the Auditor is acceptable to the Representative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14. <u>FINRA</u>. For a period of ninety (90) days from the later of the Closing Date or the Option Closing
Date, the Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i)
any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company's securities or (iii)
any beneficial owner of the Company's unregistered equity securities which were acquired during the 180 days immediately preceding
the filing of the original Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in the
Offering (as determined in accordance with the rules and regulations of FINRA).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15. <u>No Fiduciary Duties</u>. The Company acknowledges and agrees that the Underwriters' responsibility
to the Company is solely contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed
to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with
the Offering and the other transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.16. <u>Company Lock-Up</u>. The Company, on behalf of itself and any successor entity, agrees that, without
the prior written consent of the Representative, it will not, for a period of twelve (12) months after the date of this Agreement (the  ***"Lock-Up Period"***), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, change the terms of, or grant any option, right or warrant to purchase, lend, or otherwise transfer or
dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable
for shares of capital stock of the Company; (ii) file or cause to be filed any registration statement with the Commission relating to
the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
of capital stock of the Company (other than pursuant to a registration statement on Form S-8 for employee benefit plans); or (iii) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital
stock of the Company, whether any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares
of capital stock of the Company or such other securities, in cash or otherwise. The restrictions contained in this section shall
not apply to (i) the Shares and the Representative's Warrants and Representative Warrant Shares to be sold hereunder; (ii) the issuance
by the Company of Class A Shares or Class B Shares upon the exercise of an outstanding option or warrant or the conversion of a security
outstanding on the date hereof or disclosed in the Registration Statement and the Pricing Disclosure Package; (iii) the issuance of Class
A Shares or Class B Shares pursuant to the Company's existing stock option or bonus plans as disclosed in the Registration Statement
and the Pricing Disclosure Package, (iv) Class A Shares or Class B Shares, options or convertible securities issued to banks, equipment
lessors or other financial institutions, or to real property lessors, pursuant to an equipment leasing or real property leasing transaction
approved by a majority of the disinterested directors of the Company; or (v) Class A Shares or Class B Shares, options or convertible
securities issued in connection with sponsored research, collaboration, technology license, development, marketing, investor relations
or other similar agreements or strategic partnerships approved by a majority of the disinterested directors of the Company, provided the
recipient of any such Class A Shares or Class B Shares or other securities issued or granted pursuant to clause (iv), or (v) of this <u>Section 3.15</u> during the Lock-Up Period shall enter into a Lock-Up Agreement. The Company agrees not to accelerate the vesting of any option or warrant
or allow the lapse of any repurchase right prior to the expiration of the Lock-Up Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17. <u>Release of Lock-up Period</u>. If the Representative, in its sole discretion, agrees to release or
waive the restrictions set forth in the Lock-Up Agreements described in <u>Section 1.1</u> hereof for an officer, director or shareholder
of the Company and provides the Company with notice of the impending release or waiver at least three (3) Business Days before the effective
date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release through a major news
service at least two (2) Business Days before the effective date of the release or waiver.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.18. <u>Blue Sky Qualifications</u> *.* The Company shall use its commercially reasonable efforts, in cooperation
with the Underwriters, if necessary, to qualify the Shares for offering and sale under the applicable securities laws of such states and
other jurisdictions (domestic or foreign) as the Representative may designate and to maintain such qualifications in effect so long as
required to complete the distribution of the Shares; *provided*, *however*, that the Company shall not be obligated to file
any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which
it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19. <u>Reporting Requirements</u> *.* The Company, during the period when a prospectus relating to the
Shares is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all
documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and
Exchange Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Shares as may be required
under Rule 463 under the Securities Act Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.20. <u>Tail Financing</u>. If the Company consummates any public or private offering, capital raising transaction
or other financing of any kind (a  ***"Tail Financing"***) during the 12-month period following the completion of the
Offering (the  ***"Tail Term"***), to the extent any such Tail Financing is provided to the Company, in whole or in
part, by investors whom Revere had contacted or introduced to the Company (the  ***"Revere Contacts"***) during the
Tail Term, then the Company shall, in connection with each Tail Financing during the Tail Term, (i) pay to Revere a cash fee, or as to
an underwritten offering an underwriting discount, equal to 7.0% of the aggregate gross proceeds raised from the Revere Contacts (and
if a Tail Financing includes an over-allotment option or other additional investment component, 7.0% of the aggregate gross proceeds of
such proportional number of ordinary shares attributable to the Representatives Contacts participating in such Tail Financing and sold
pursuant to such over-allotment option or other investment component) and (ii) issue to Revere or its designees warrants ( ***"Tail Warrants"***) to purchase that number of Class B Shares equal to 7.0% of the aggregate number of Class B Shares (or Class B
Share equivalents, if applicable) placed or sold to, or received by, the Revere Contacts (and if a Tail Financing includes an over-allotment
option or other additional investment component, Tail Warrants equal to 7.0% of such proportional number of Class B Shares attributable
to the Revere Contacts participating in such Tail Financing and sold pursuant to such over-allotment option or other investment component).
The Tail Warrants shall be in a customary form reasonably acceptable to Revere, have a term of five (5) years, contain and piggyback registration
rights, and have an exercise price equal to 100% of the offering price per share (or unit, if applicable) in the applicable Tail Financing
and if such offering price is not available, the market price of the Class B Shares or other securities offered on the date a Tail Financing
is commenced (the  ***"Tail Offer Price"***). If Tail Warrants are issued to investors in a Tail Financing, the Tail
Warrants shall have the same terms as the warrants issued to investors in the applicable Tail Financing, except that such Tail Warrants
shall have an exercise price equal to 100% of the Tail Offer Price.

&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Conditions of Underwriters' Obligations**. The
obligations of the Underwriters to purchase and pay for the Shares, as provided herein, shall be subject to (i) the continuing accuracy
of the representations and warranties of the Company as of the date hereof and as of each of the Closing Date and the Option Closing
Date, if any, (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance
by the Company of its obligations hereunder; and (iv) the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. <u>Regulatory Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.1. *<u>Effectiveness of Registration Statement; Rule 430A Information</u>* . The Registration Statement
has become effective not later than 5:00 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented
to in writing by you, and, at the Closing Date and the Option Closing Date, if any, no stop order suspending the effectiveness of the
Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending
the use of any Preliminary Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted
or are pending or, to the Company's knowledge, contemplated by the Commission. The Company has complied with each request (if any)
from the Commission for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission
in the manner and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing
such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.2. *<u>FINRA Clearance</u>* . On or before the date of this Agreement, the Representative shall have
received clearance from FINRA as to the amount of compensation allowable or payable to the Underwriters as described in the Registration
Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.3. *<u>Exchange Share Market Clearance</u>* . On the Closing Date, the Firm Shares shall have been approved
for listing on the Exchange, subject only to official notice of issuance. On the first Option Closing Date (if any), the Option Shares
shall have been approved for listing on the Exchange, subject only to official notice of issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. <u>Company Counsel Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.1. *<u>Closing Date Opinions of Counsels</u>* . On the Closing Date, the Representative shall have received
the favorable opinion of Bevilacqua PLLC, U.S. counsel for the Company, Philip Lee LLP, Irish counsel for the Company, and DCS & Partner,
Italian counsel for the Company, in form and substance reasonably satisfactory to Representative's Counsel addressed to the Representative
and stating that such opinions may be relied upon Representative's Counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.2. *<u>Option Closing Date Opinion of Counsel</u>* . On the Option Closing Date, if any, the Representative
shall have received the favorable opinions, Bevilacqua PLLC, U.S. counsel for the Company, Philip Lee LLP, Irish counsel for the Company,
and DCS & Partner, Italian counsel for the Company, dated the Option Closing Date, addressed to the Representative and in form and
substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made by such counsel
in their opinions delivered on the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.3. *<u>Reliance</u>* . In rendering such opinions, such counsel may rely: (i) as to matters involving
the application of laws other than the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel
deems proper and to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory
to the Representative) of other counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to
matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company and officers of
departments of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company, *provided* that copies of any such statements or certificates shall be delivered to Representative's Counsel if requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3. <u>Comfort Letters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.1. *<u>Cold Comfort Letter</u>* . At the time this Agreement is executed, the Representative shall have
received a cold comfort letter containing statements and information of the type customarily included in accountants' comfort letters
with respect to the financial statements and certain financial information contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, addressed to the Representative and in form and substance satisfactory in all respects to the Representative,
dated as of the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.2. *<u>Bring-down Comfort Letter</u>* . At each of the Closing Date and the Option Closing Date, if any,
the Representative shall have received from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable,
to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to <u>Section 4.3</u>, except that
the specified date referred to shall be a date not more than three (3) Business Days prior to the Closing Date or the Option Closing Date,
as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4. <u>Officers' Certificates</u> *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4.1. *<u>Officers' Certificate</u>* . The Company shall have furnished to the Representative a certificate,
dated the Closing Date and any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer and its
Chief Financial Officer stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package,
any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as
of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include
any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option
Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date
(or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto, as
of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not
misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement
or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) to the best of their knowledge after
reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the representations
and warranties of the Company in this Agreement are true and correct in all material respects (except for those representations and warranties
qualified as to materiality, which shall be true and correct in all respects and except for those representations and warranties which
refer to facts existing at a specific date, which shall be true and correct as of such date) and the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing
Date if such date is other than the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial
statements included or incorporated by reference in the Pricing Disclosure Package, a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4.2. *<u>Secretary's Certificate</u>* . At each of the Closing Date and the Option Closing Date,
if any, the Representative shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing
Date or the Option Date, as the case may be, respectively, certifying: (i) that the Charter is true and complete, has not been modified
and is in full force and effect; (ii) that the resolutions of the Company's Board of Directors (and any pricing committee thereof)
relating to the Offering are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence
between the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred
to in such certificate shall be attached to such certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5. <u>No Material Changes</u>. Prior to and on each of the Closing Date and each Option Closing Date, if
any: (i) there shall have been no Material Adverse Change in the condition or prospects or the business activities, financial or otherwise,
of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company
or any Insider before or by any court or U.S. federal or state commission, board or other administrative agency wherein an unfavorable
decision, ruling or finding may reasonably be expected to cause a Material Adverse Change, except as set forth in the Registration Statement,
the Pricing Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings
therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package
and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein
in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements
of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the
Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6. <u>Delivery of Agreements</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6.1. *<u>Lock-Up Agreements</u>* . On or before the date of this Agreement, the Company shall have delivered
to the Representative executed copies of the Lock-Up Agreements by the parties listed on Schedule 5 hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6.2. *<u>Representative's Warrant</u>* . On the Closing date, the Company shall have delivered to
the Representative an executed copy of the Representative's Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7. <u>Additional Documents</u>. At the Closing Date and at each Option Closing Date (if any), Representative's
Counsel shall have been furnished with such documents and opinions as they may require for the purpose of enabling Representative's
Counsel to deliver an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or
the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and
sale of the Shares and the Representative's Warrants as herein contemplated shall be satisfactory in form and substance to the Representative
and Representative's Counsel.

**5.** **Indemnification**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1. <u>Indemnification of the Underwriters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.1. *<u>General</u>* . Subject to the conditions set forth below, the Company agrees to indemnify and
hold harmless each Underwriter, its affiliates and each of its and their respective directors, officers, members, employees, representatives,
partners, shareholders, affiliates, counsel, and agents and each person, if any, who controls any such Underwriter within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the  ***"Underwriter Indemnified Parties,"*** and each an  ***"Underwriter Indemnified Party"***), against any and all loss, liability, claim,
damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between
any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party,
or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common
law or otherwise or under the laws of foreign countries (a  ***"Claim"***), arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained, or the omission or alleged omission therefrom of a material fact required
to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading,
in (A) the Registration Statement, the Pricing Disclosure Package, any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing
Prospectus or in any Written Testing-the-Waters Communication (as from time to time each may be amended and supplemented); (B) any materials
or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including
any "road show" or investor presentations made to investors by the Company (whether in person or electronically); or (C) any
application or other document or written communication (in this <u>Section 4.7</u>, collectively called "application") executed
by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Shares and Representative's
Warrants under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any
other national securities exchange; *unless*, with respect to each subsection (A) through (C), such statement or omission was
made in reliance upon, and in conformity with, the Underwriters' Information. With respect to any untrue statement or omission or
alleged untrue statement or omission made in the Registration Statement, Pricing Disclosure Package or Prospectus, the indemnity agreement
contained in this <u>Section 5.1</u> shall not inure to the benefit of any Underwriter Indemnified Party to the extent that any loss,
liability, claim, damage or expense of such Underwriter Indemnified Party results from the fact that a copy of the Prospectus was not
given or sent to the person asserting any such loss, liability, claim or damage at or prior to the written confirmation of sale of the
Shares to such person as required by the Securities Act and the Securities Act Regulations, and if the untrue statement or omission has
been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the Company with its
obligations under <u>Section 3.2.5</u> hereof. The Company also agrees that it will reimburse each Underwriter Indemnified Party
for all reasonable fees and expenses (including but not limited to any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between
any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party,
or otherwise) (collectively, the  ***"Expenses"***), and further agrees wherever and whenever possible to advance payment
of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending any Claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.2. *<u>Procedure</u>* . If any action is brought against an Underwriter Indemnified Party in respect
of which indemnity may be sought against the Company pursuant to <u>Section 5.1</u>, such Underwriter Indemnified Party shall promptly
notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including the
employment and fees of counsel (subject to the approval of such Underwriter Indemnified Party (which approval shall not be unreasonably
delayed or withheld)) and payment of actual expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter
Indemnified Party shall have the right to employ its or their own counsel in any such case, and the fees and expenses of such counsel
shall be at the expense of the Company and shall be advanced by the Company; *provided*, *however*, that the Company shall not
be obligated to bear the reasonable fees and expenses of more than one firm of attorneys selected by the Underwriter Indemnified Party
(in addition to local counsel). Notwithstanding anything to the contrary contained herein, and provided that the Company has timely honored
its obligations under <u>Section 4.7</u>, the Underwriter Indemnified Party shall not enter into any settlement without the prior
written consent (which shall not be unreasonably delayed or withheld) of the terms of any settlement by the Company. The Company shall
not be liable for any settlement of any action effected without its prior written consent (which shall not be unreasonably delayed or
withheld). In addition, the Company shall not, without the prior written consent of the Underwriters (which consent shall not be unreasonably
delayed or withheld), settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened
action in respect of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether or not such Underwriter
Indemnified Party is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release
of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified Party, from all liabilities, expenses and claims arising
out of such action for which indemnification or contribution may be sought and (ii) does not include a statement as to or an admission
of fault, culpability or a failure to act, by or on behalf of any Underwriter Indemnified Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2. <u>Indemnification of the Company</u>. Each Underwriter, severally and not jointly, agrees to indemnify
and hold harmless the Company, its directors, its officers who signed the Registration Statement and persons who control the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim,
damage and expense described in the foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect
to such losses, liabilities, claims, damages and expenses (or actions in respect thereof) which arise out of or are based upon untrue
statements or omissions, or alleged untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the
Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in conformity
with, the Underwriters' Information. In case any action shall be brought against the Company or any other person so indemnified
based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement
thereto or any application, and in respect of which indemnity may be sought against any Underwriter, such Underwriter shall have the rights
and duties given to the Company, and the Company and each other person so indemnified shall have the rights and duties given to the several
Underwriters by the provisions of <u>Section 5.1.1</u>. The Company agrees promptly to notify the Representative of the commencement of
any litigation or proceedings against the Company or any of its officers, directors or any person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale
of the Shares or in connection with the Registration Statement, the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing
Prospectus or any Written Testing-the-Waters Communication.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3. <u>Contribution</u> *.* If the indemnification provided for in this <u>Section 4.7</u> shall
for any reason be unavailable to or insufficient to hold harmless an indemnified party under <u>Section 5</u> or <u>Section 5.1.2</u> in respect of any liabilities and Expenses referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified
party, contribute to the amount paid or payable by such indemnified party as a result of such liabilities and Expenses, (i) in such proportion
as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and each of the Underwriters, on the
other hand, from the Offering, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company,
on the one hand, and the Underwriters, on the other hand, in connection with the matters as to which such liabilities or Expenses relate,
as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds actually received by
the Company from the Offering of the Shares purchased under this Agreement (before deducting expenses) received by the Company bear to
the total underwriting discounts and commissions actually received by the Underwriters in connection with the Offering, in each case as
set forth in the table on the cover page of the Prospectus. The relative fault of the Company, on the one hand, and the Underwriters,
on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters,
on the other, and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such untrue
statement, omission, act or failure to act; *provided* that the parties hereto agree that the written information furnished to the
Company through the Representative by or on behalf of any Underwriter for use in any Preliminary Prospectus, any Registration Statement
or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriters' Information. The Company and
the Underwriters agree that it would not be just and equitable if contributions pursuant to this <u>Section 5.2</u> were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which
does not take into account the equitable considerations referred to above in this <u>Section 5.2</u>. Notwithstanding the above,
no person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution
from a party who was not guilty of such fraudulent misrepresentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4. <u>Limitation</u>. The Company also agrees that no Underwriter Indemnified Party shall have any liability
(whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or
to be rendered by any Underwriter Indemnified Party pursuant to this Agreement, the transactions contemplated thereby or any Underwriter
Indemnified Party's actions or inactions in connection with any such advice, services or transactions, except to the extent that
a court of competent jurisdiction has made a finding that liabilities (and related Expenses) of the Company have resulted from such Underwriter
Indemnified Party's fraud, bad faith, gross negligence or willful misconduct in connection with any such advice, actions, inactions
or services or such Underwriter Indemnified Party's breach of this Agreement or any obligations of confidentiality owed to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5. <u>Survival & Third-Party Beneficiaries</u>. The advancement, reimbursement, indemnity and contribution
obligations set forth in this <u>Section 4.7</u> shall remain in full force and effect regardless of any termination of, or the completion
of any Underwriter Indemnified Party's services under or in connection with, this Agreement. Each Underwriter Indemnified Party
is an intended third-party beneficiary of this <u>Section 4.7</u>, and has the right to enforce the provisions of <u>Section 4.7</u> as if he/she/it was a party to this Agreement.

**6.** **Default by an Underwriter**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1. <u>Default Not Exceeding 10% of Firm Shares or Option Shares</u> *.* If any Underwriter or Underwriters
shall default in its or their obligations to purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised
hereunder, and if the number of the Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate
10% of the number of Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option
Shares to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments
hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2. <u>Default Exceeding 10% of Firm Shares or Option Shares</u>. In the event that the default addressed
in <u>Section 6</u> relates to more than 10% of the Firm Shares or Option Shares, you may in your discretion arrange for yourself
or for another party or parties to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein.
If, within one (1) Business Day after such default relating to more than 10% of the Firm Shares or Option Shares, you do not arrange for
the purchase of such Firm Shares or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within
which to procure another party or parties satisfactory to you to purchase said Firm Shares or Option Shares on such terms. In the event
that neither you nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in
this <u>Section 5.5</u>, this Agreement will automatically be terminated by you or the Company without liability on the part of the
Company (except as provided in <u>Section 4.7</u> and <u>Section 8.25</u> hereof) or the several Underwriters (except as provided
in Section 4.75 hereof); *provided*, *however*, that if such default occurs with respect to the Option Shares, this Agreement
will not terminate as to the Firm Shares; and *provided*, *further*, that nothing herein shall relieve a defaulting Underwriter
of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3. <u>Postponement of Closing Date</u>. In the event that the Firm Shares or Option Shares to which the default
relates are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or
the Company shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding
five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure
Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration
Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary.
The term  ***"Underwriter"*** as used in this Agreement shall include any party substituted under this <u>Section 5.5</u> with like effect as if it had originally been a party to this Agreement with respect to such Firm Shares or Option Shares.

**7.** **[INTENTIONALLY OMITTED**.]

**8.** **Effective Date of this Agreement and Termination Thereof**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1. <u>Effective Date</u>. This Agreement shall become effective when both the Company and the Representative
have executed the same and delivered counterparts of such signatures to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2. <u>Termination</u> *.* The Representative shall have the right to terminate this Agreement at any
time prior to any Closing Date, (i) if any domestic or international event or act or occurrence has materially disrupted, or in your opinion
will in the immediate future materially disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock
Exchange or The Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall
have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other
government authority having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase in major
hostilities as in the reasonable judgment of the Representative is material and adverse and would make it impracticable to proceed with
the Offering, sale and/or delivery of the Shares or to enforce contracts made by the Underwriters for the sale of the Shares; or (iv)
if a banking moratorium has been declared by a New York State or U.S. federal authority; or (v) if a moratorium on foreign exchange trading
has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall have sustained
a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or
not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Shares or Option
Shares; or (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the
Representative shall have become aware after the date hereof of such a Material Adverse Change, or such adverse material change in general
market conditions as in the Representative's judgment would make it impracticable to proceed with the offering, sale and/or delivery
of the Shares or to enforce contracts made by the Underwriters for the sale of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3. <u>Expenses</u> *.* Notwithstanding anything to the contrary in this Agreement, except in the case
of a default by the Underwriters, pursuant to <u>Section 6.1</u> above, in the event that this Agreement shall not be carried out
for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall
be obligated to pay to the Underwriters their actual and accountable out-of-pocket expenses related to the transactions contemplated herein
then due and payable up to the amounts set forth in Section 3.8 and upon demand the Company shall pay such amount thereof to the
Representative on behalf of the Underwriters; *provided*, *however*, that such expense cap in no way limits or impairs the indemnification
and contribution provisions of this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed
to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4. <u>Indemnification</u>. Notwithstanding any contrary provision contained in this Agreement, any election
hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of <u>Section 4.7</u> shall remain in full force and effect and shall not be in any way affected by, such election or termination or failure to carry
out the terms of this Agreement or any part hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5. <u>Representations, Warranties, Agreements to Survive</u>. All representations, warranties and agreements
contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full
force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any
person controlling any Underwriter, its officers or directors or any person controlling the Company or (ii) delivery of and payment for
the Shares.

**9.** **Miscellaneous**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1. <u>Notices</u> *.* All communications
hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return
receipt requested), emailed, personally delivered or sent by facsimile transmission and confirmed and shall be deemed given when so delivered
or faxed and confirmed or if mailed, two (2) days after such mailing.

If to the Representative:

**Revere Securities, LLC**

650 Fifth Ave., 35<sup>th</sup> Floor<br> New York, NY 10019

Attn: Kyle Wool, President

Email: kwool@reversecurities.com

 

*With a copy (which shall not constitute notice) to:*

**Carmel, Milazzo & Feil LLP**

55 West 39<sup>th</sup> Street, 18th Floor

New York, NY 10018

Attention: Ross Carmel, Esq.

Email: rcarmel@cmfllp.com

If to the Company:

**Brera Holdings PLC**

Connaught House, 5th Floor

One Burlington Road

Dublin 4, D04 C5Y6, Ireland

Attention: Daniel J. McClory, Executive Chairman

Email: dan@breraholdings.com

 

*With a copy (which shall not constitute notice) to*:

**Bevilacqua PLLC** 

1050 Connecticut Avenue, NW, Suite 500

Washington, DC 20036

Attention: Louis A. Bevilacqua, Esq.

Email: lou@bevilacquapllc.com

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2. <u>Headings</u> *.* The headings contained herein are for the sole purpose of convenience of reference,
and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3. <u>Amendment</u> *.* This Agreement may only be amended by a written instrument executed by each of
the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4. <u>Entire Agreement</u> *.* This Agreement (together with the other agreements and documents being
delivered pursuant to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the
subject matter hereof and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect
to the subject matter hereof. Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto
that all other terms and conditions of that certain engagement letter between the Company and Representative dated as of September 26,
2022 shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5. <u>Binding Effect</u> *.* This Agreement shall inure solely to the benefit of and shall be binding
upon the Representative, the Underwriters, the Company and the controlling persons, directors and officers referred to in <u>Section 4.7</u> hereof, and their respective successors, legal representatives, heirs and assigns, and no other person shall have or be construed to have
any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained.
The term  ***"successors and assigns"*** shall not include a purchaser, in its capacity as such, of securities from
any of the Underwriters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6. <u>Governing Law; Consent to Jurisdiction; Trial by Jury</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6.1. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State
of New York, without giving effect to conflict of laws principles thereof. To the extent that the Company has or hereafter may acquire
any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to
itself or its property, the Company irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any such suit,
action or proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6.2. By the execution and delivery of this Agreement, the Company hereby irrevocably designates and appoints
Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168 as its authorized agent upon whom process may be
served in any suit, proceeding or other action against it instituted by any Underwriter or by any person controlling an Underwriter as
to which such Underwriter or any such controlling person is a party and based upon this Agreement, or in any other action against the
Company in the New York Supreme Court, County of New York or the United States District Court for the Southern District of New York, arising
out of the offering made by the Preliminary Prospectus, the Prospectus, the Registration Statement or any purchase or sale of Shares in
connection therewith. The Company expressly accepts jurisdiction of any such court in respect of any such suit, proceeding or other action
and, without limiting other methods of obtaining jurisdiction, expressly submits to nonexclusive personal jurisdiction of any such court
in respect of any such suit, proceeding or other action. Such designation and appointment shall be irrevocable, unless and until a successor
authorized agent in the County and State of New York reasonably acceptable to the Representative shall have been appointed by the Company,
such successor shall have accepted such appointment and written notice thereof shall have been given to the Underwriters. The Company
further agrees that service of process upon its authorized agent or successor shall be deemed in every respect personal service of process
upon the Company in any such suit, proceeding or other action. In the event that service of any process or notice of motion or other application
to any such court in connection with any such motion in connection with any such action or proceeding cannot be made in the manner described
above, such service may be made in the manner set forth in conformance with the Hague Convention on the Service Abroad of Judicial and
Extrajudicial Documents on Civil and Commercial Matters or any successor convention or treaty. The Company hereby irrevocably waives any
objection that it may have or hereafter have to the laying of venue of any such action or proceeding arising out of or based on the Shares
or this Agreement or otherwise relating to the offering, issuance and sale of the Shares in any U.S. federal or state court sitting in
the County of New York and hereby further irrevocably waives any claim that any such action or proceeding in any such court has been brought
in an inconvenient forum. The Company agrees that any final judgment after exhaustion of all appeals or the expiration of time to appeal
in any such action or proceeding arising out of the sale of the Shares or this Agreement rendered by any such U.S. federal court or state
court shall be conclusive and may be enforced in any other jurisdiction by suit on the judgment or in any other manner provided by law.
Nothing contained in this Agreement shall affect or limit the right of the Underwriters or any person controlling an Underwriter to serve
any process or notice of motion or other application in any other manner permitted by law or limit or affect the right of the Underwriters
or any person controlling an Underwriter to bring any action or proceeding against the Company or any of its properties in the courts
of any other jurisdiction. The Company further agrees to take any and all action, including the execution and filing of all such instruments
and documents, as may be necessary to continue such designations and appointments or such substitute designations and appointments in
full force and effect. The Company hereby agrees with the Underwriters to the exclusive jurisdiction of the New York Supreme Court, County
of New York or the United States District Court for the Southern District of New York in connection with any action or proceeding arising
from the sale of the Shares or this Agreement brought by the Company, the Underwriters or any person controlling an Underwriter. The Company
(on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates) and each of the Underwriters
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6.3. The Company agrees that in any suit (whether in a court in the United States or elsewhere) seeking enforcement
of this Agreement or provisions of this Agreement, if the plaintiffs therein seek a judgment in either United States dollars or EUR euros,
the Company will not interpose any defense or objection to or otherwise oppose judgment, if any, being awarded in such currencies. The
Company agrees that it will not initiate or seek to initiate any action, suit or proceeding, in any other jurisdiction other than in the
United States, seeking damages in respect of or for the purpose of obtaining any injunction or declaratory judgment against the enforcement
of, or a declaratory judgment concerning any alleged breach by the Company or other claim by the Underwriters, or any person controlling
an Underwriter in respect of this Agreement or any of the Underwriters' rights under this Agreement, including without limitation
any action, suit or proceeding challenging the enforceability of or seeking to invalidate in any respect the submission by the Company
hereunder to the jurisdiction of the courts or the designation of the laws as the law applicable to this Agreement, in each case as set
forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6.4. The Company agrees that if any payment of any sum due under this Agreement from the Company is made to
or received by the Underwriters or any controlling person of any Underwriter in a currency other than freely transferable United States
dollars, whether by judicial judgment or otherwise, the obligations of the Company under this Agreement shall be discharged only to the
extent of the net amount of freely transferable United States dollars that the Underwriters or such controlling persons, as the case may
be, in accordance with normal bank procedures, are able to lawfully purchase with such amount of such other currency. To the extent that
the Underwriters or such controlling persons are not able to purchase sufficient United States dollars with such amount of such other
currency to discharge the obligations of the Company to the Underwriters or such controlling persons, the obligations of the Company shall
not be discharged with respect to such difference, and any such undischarged amount will be due as a separate obligation and shall not
be affected by payment of or judgment being obtained for any other sums due under or in respect of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6.5. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from
the other party(ies) all of its reasonable attorneys' fees and expenses relating to such action or proceeding and/or incurred in
connection with the preparation therefor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7. <u>Execution in Counterparts</u> *.* This Agreement may be executed in one or more counterparts, and
by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together
shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties
hereto and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf
transmission shall constitute valid and sufficient delivery thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.8. <u>Waiver, etc</u>. The failure of any of the parties hereto to at any time enforce any of the provisions
of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this
Agreement or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement.
No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth
in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of
any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance
or non-fulfillment.

*[Signature Page Follows]*

 

If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **BRERA HOLDINGS PLC** | **BRERA HOLDINGS PLC** | **BRERA HOLDINGS PLC** |
| By: | /s/ Daniel J. McClory | /s/ Daniel J. McClory |
|  | Name: | Daniel J. McClory |
|  | Title: | Executive Chairman |

---

Confirmed as of the date first written above mentioned, on behalf of itself and as Representative of the several Underwriters named on Schedule 1 hereto:

---

| | |
|:---|:---|
| **REVERE SECURITIES, LLC** | **REVERE SECURITIES, LLC** |
| By: | /s/ Arthur DeFilippo |
| Name: | Arthur DeFilippo |
| Title: | Managing Director |

---

**<u>SCHEDULE 1</u>**

**UNDERWRITERS**

---

| | | |
|:---|:---|:---|
| ***Underwriter*** | **Total Number of Firm<br> Shares to be Purchased** | **Number of<br> Additional Option<br> Shares <br> to be Purchased<br> if the<br> Over-Allotment<br> Option is Fully<br> Exercised** |
| Revere Securities, LLC | 1500000 | 225000 |
| **TOTAL** | 1500000 | 225000 |

---

**<u>SCHEDULE 2</u>**

**Pricing Information**

---

| | |
|:---|:---|
| Number of Firm Shares: | 1500000.0 |
| Number of Option Shares: | 225000.0 |
| Public Offering Price per Firm Share: | $5.0 |
| Public Offering Price per Option Share: | $5.0 |
| Underwriting Discount per Firm Share: | $0.35 |
| Underwriting Discount per Option Share: | $0.35 |
| Proceeds to Company per Firm Share (before expenses): | $4.65 |
| Proceeds to Company per Option Share (before expenses): | $4.65 |

---

**<u>SCHEDULE 3</u>**

**Issuer General Use Free Writing Prospectuses**

None.

**<u>SCHEDULE 4</u>**

**Written Testing-the-Waters Communications**

None.

**<u>SCHEDULE 5</u>**

**List of Lock-Up Parties<sup>1</sup>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Sergio Carlo Scalpelli, Chief Executive Officer and Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Alessandro Aleotti, Chief Strategy Officer and Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Amedeo Montonati, Chief Financial Officer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Daniel Joseph McClory, Executive Chairman and Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Alberto Libanori, Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Christopher Paul Gardner, Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Pietro Bersani, Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Goran Pandev, Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Niteroi Spa

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. Pinehurst Partners LLC

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Marco Sala

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Leonardo Aleotti

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. KAP Global Holding Limited

<sup>1</sup> NTD: subject to the inclusion of additional parties based on completed F-1 beneficial ownership table.

**<u>EXHIBIT A</u>**

**Form of Representative's Warrant**

**<u>EXHIBIT B</u>**

**Form of Lock-Up Agreement**

## Exhibit 4.1

**Exhibit 4.1**

**FORM OF REPRESENTATIVE WARRANT**

THE REGISTERED HOLDER OF THIS WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, OR ASSIGN THIS WARRANT EXCEPT AS PROVIDED HEREIN AND IN THE UNDERWRITING AGREEMENT (AS DEFINED BELOW) AND THE REGISTERED HOLDER OF THIS WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE, OR HYPOTHECATE THIS WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING JANUARY 26, 2023 (THE ***"EFFECTIVE DATE"***), THE COMMENCEMENT OF SALES OF CLASS B ORDINARY SHARES IN THE PUBLIC OFFERING (THE ***"OFFERING"***), TO ANYONE OTHER THAN (I) REVERE SECURITIES, LLC, OR AN UNDERWRITER OR A SELECTED DEALER PARTICIPATING IN THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF REVERE SECURITIES, LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER, EACH OF WHOM SHALL HAVE AGREED TO THE RESTRICTIONS CONTAINED HEREIN, IN THE UNDERWRITING AGREEMENT, AND IN ACCORDANCE WITH FINRA RULE 5110(E)(1).

THIS WARRANT IS NOT EXERCISABLE PRIOR TO JULY 26, 2023. VOID AFTER 5:00 P.M., EASTERN TIME, JANUARY 26, 2028.

**CLASS B ORDINARY SHARE PURCHASE WARRANT**

**BRERA HOLDINGS PLC** 

Warrant Shares: 105,000 Issue Date: January 31, 2023 <br> Initial Exercise Date: July 26, 2023

**THIS CLASS B ORDINARY SHARE PURCHASE WARRANT** (the ***"Warrant"***) certifies that for value received, Revere Securities, LLC, or its assignees (the ***"Holder"***) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the initial exercise date set forth above (the ***"Initial Exercise Date"***) and on or prior to 5:00 p.m. (Eastern Time) on January 26, 2028 (the ***"Termination Date"***) but not thereafter, to subscribe for and purchase up to 105,000 Class B Ordinary Shares, nominal value $0.005 per share (the ***"Class B Shares"***), of Brera Holdings PLC, an Irish holding company (the ***"Company"***), subject to adjustment hereunder (the ***"Warrant Shares"***). The purchase price of one share of Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in <u>Section 2(b)</u>. This Warrant is being issued pursuant to the terms of the Underwriting Agreement (as defined in <u>Section 1</u>). Capitalized terms used herein and not otherwise defined in this Warrant shall have the meanings set forth in the Underwriting Agreement.

**Section 1. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this <u>Section 1</u>:**

***"Affiliate"*** means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

***"Business Day"*** means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

***"Commission"*** means the United States Securities and Exchange Commission.

***"Class A Shares"*** means the Class A Ordinary Shares of the Company, nominal value $0.005 per share.

***"Class B Shares"*** means the Class B Ordinary Shares of the Company, nominal value $0.005 per share.

***"Exchange Act"*** means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

***"Ordinary Shares"*** means the Class A Shares and the Class B Shares.

***"Person"*** means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

***"Securities Act"*** means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

***"Trading Day"*** means a day on which the Class B Shares are traded on a Trading Market.

***"Trading Market"*** means any of the following markets or exchanges on which the Class B Shares are listed or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, or the NYSE American (or any successors to any of the foregoing).

***"Transfer Agent"*** means the SEC registered transfer agent of the Company.

***"Underwriting Agreement"*** means that certain underwriting agreement entered into by and between Revere Securities, LLC, as the representatives of the underwriters, if any, listed on Schedule 1 thereto, and the Company, dated as of January 26, 2023.

**Section 2. Exercise.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before 5:00 P.M. (Eastern Time) on the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form of Exhibit A attached hereto (the ***"Notice of Exercise"***). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <u>Section 2(c)(i)</u> herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier's check drawn on a United States bank. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. **The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Exercise Price</u>. The exercise price per share of Class B Shares under this Warrant shall be **$5.00** subject to adjustment hereunder (the ***"Exercise Price"***).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Mechanics of Exercise</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (***"DWAC"***) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the ***"Warrant Share Delivery Date"***). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price is received by the Warrant Share Delivery Date. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, ***"Standard Settlement Period"*** means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Class B Shares as in effect on the date of delivery of the Notice of Exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <u>Section 2(c)(i)</u> by the Warrant Share Delivery Date (subject to receipt of the aggregate Exercise Price for the applicable exercise, then the Holder will have the right to rescind such exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Holder's Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to <u>Section 2</u> or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder's Affiliates (such Persons, ***"Attribution Parties"***)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Class B Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Class B Shares issuable upon exercise of this Warrant with respect to which such determination is being made but shall exclude the number of Class B Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company (including, without limitation, any other Class B Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this <u>Section 2(d)</u>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <u>Section 2(d)</u> applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <u>Section 2(d)</u>, in determining the number of outstanding Class B Shares, a Holder may rely on the number of outstanding Class B Shares as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Class B Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of Class B Shares then outstanding. In any case, the number of outstanding Class B Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Class B Shares was reported. The ***"Beneficial Ownership Limitation"*** shall be 4.99% of the number of Class B Shares outstanding immediately after giving effect to the issuance of Class B Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this <u>Section 2(d)</u>, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Class B Shares outstanding immediately after giving effect to the issuance of Class B Shares upon exercise of this Warrant held by the Holder and the provisions of this <u>Section 2(d)</u> shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup>st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this <u>Section 2(d)</u> to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

**Section 3. <u>Certain Adjustments</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on Class B Shares or any other equity or equity equivalent securities payable in Class B Shares (which, for avoidance of doubt, shall not include any Class B Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Class B Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Class B Shares into a smaller number of shares, or (iv) issues by reclassification of Class B Shares any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Class B Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Class B Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this <u>Section 3(a)</u> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to <u>Section 3(a)</u> above, if at any time the Company grants, issues or sells any Class B Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of ordinary shares (the ***"Purchase Rights"***), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Class B Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Class B Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Class B Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash) or other distribution of its assets (or rights to acquire its assets) to holders of Class B Shares, by way of return of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a ***"Distribution"***), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Class B Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Class B Shares are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Class B Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, exclusive license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Share is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates an ordinary share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Ordinary Shares (not including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a ***"Fundamental Transaction"***), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in <u>Section 2(d)</u> on the exercise of this Warrant), the number of Class B Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the ***"Alternate Consideration"***) receivable as a result of such Fundamental Transaction by a holder of the number of Class B Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in <u>Section 2(d)</u> on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Class B Share in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Class B Shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder's option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <u>provided</u>, <u>however</u>, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Class B Shares in connection with the Fundamental Transaction, whether that consideration be in the form of cash, share or any combination thereof, or whether the holders of Class B Shares are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <u>provided</u>, <u>further</u>, that if holders of Class B Shares are not offered or paid any consideration in such Fundamental Transaction, such holders of Class B Shares will be deemed to have received ordinary shares (or equivalent thereof) of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. ***"Black Scholes Value"*** means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the ***"OV"*** function on Bloomberg, L.P. (***"Bloomberg"***) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or by delivery of such other consideration, as applicable) within five (5) Trading Days of the Holder's election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the ***"Successor Entity"***) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this <u>Section 3(a)</u> pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Class B Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of Class B Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the ***"Company"*** shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Calculations</u>. All calculations under this <u>Section 3</u> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <u>Section 3</u>, the number of Class B Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Class B Shares (excluding treasury shares, if any) issued and outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Notice to Holder</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this <u>Section 3</u>, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares, (C) the Company shall authorize the granting to all holders of Ordinary Share rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Company's Ordinary Shares, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Class B Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 6-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

**Section 4. *"Piggy-Back"* Registration.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Grant of Right</u>. Unless a registration statement covering the exercise of this Warrant and the sale of the Warrant Shares by the Holder is in effect and available, the Holder shall have the right to include the Warrant Shares as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act, or pursuant to Form S-8 or any equivalent form) for a period of seven (7) years from the commencement of sales of the public offering pursuant to which this Warrant is being issued, pursuant to FINRA Rule 5110(g)(8)(D); <u>provided</u>, <u>however</u>, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of Class B Shares which may be included in the registration statement because, in such underwriter(s)' judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion of the Warrant Shares with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Warrant Shares shall be made pro rata among the Holders seeking to include registrable securities in proportion to the number of Warrant Shares sought to be included by such Holders; <u>provided</u>, <u>however</u>, that the Company shall not exclude any Warrant Shares unless the Company has first excluded all outstanding securities, the holders of which are not entitled to the inclusion of such securities in such registration statement or are not entitled to pro rata inclusion with the Warrant Shares. Notwithstanding the foregoing, the Company shall not be required to register any Warrant Shares pursuant to this <u>Section 4(a)</u> that are subject of a then effective registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Terms</u>. The Company shall bear all fees and expenses attendant to registering the Warrant Shares pursuant to <u>Section 4(a)</u> hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Warrant Shares. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Warrant Shares with not less than fifteen (15) days written notice prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Warrant Shares have been sold by the Holder. The Holders of the Warrant Shares shall exercise the ***"piggy-back"*** rights provided for herein by giving written notice within five (5) days of the receipt of the Company's notice of its intention to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under this <u>Section 4(b)</u>

**Section 5. Transfer of Warrant.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Transferability</u>. Pursuant to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) by operation of law or by reason of reorganization of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to any FINRA member firm participating in the offering and the officers and partners thereof, if all securities so transferred remain subject to the lock-up restriction in this <u>Section 5(a)</u> for the remainder of the time period;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if the aggregate amount of securities of the Company held by the underwriter and related persons do not exceed 1% of the securities being offered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this <u>Section 5(a)</u> for the remainder of the time period.

Subject to the foregoing restrictions and subject to compliance with any applicable securities laws and the conditions set forth in <u>Section 5(d)</u> hereof, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto as Exhibit B, duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with <u>Section 5(a)</u> as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the ***"Warrant Register"***), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, to provide to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company to the effect that the transfer of this Warrant does not require registration under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

**Section 6. Miscellaneous.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <u>Section 2(c)(i)</u>, except as expressly set forth in <u>Section 3</u>. In no event will the Company be required to net cash settle an exercise of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Authorized Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, New York County (the ***"New York Courts"***). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or an inconvenient venue for such suit, action or proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, email, or sent by a nationally recognized overnight courier service, addressed to the Company, Connaught House, 5th Floor, One Burlington Road, Dublin 4, D04 C5Y6, Ireland, Attention: Chief Executive Officer, with a copy (which shall not constitute notice hereunder) to Bevilacqua PLLC,1050 Connecticut Avenue, NW, Suite 500, Washington, DC 20036, Attn: Louis A. Bevilacqua, Esq. All notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service addressed to each Holder at the email address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email at the email address set forth in this <u>Section 6(h)</u> prior to 5:30 p.m. (Eastern Time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the email address set forth in this <u>Section 6(h)</u>on a day that is not a Trading Day or later than 5:30 p.m. (Eastern Time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given; <u>provided</u>, <u>however</u>, that notice given by email will not be effective unless either (A) a duplicate copy of such email notice is promptly given by one of the other methods described in this <u>Section 6(h)</u>or (B) the receiving party delivers a written confirmation of receipt of such notice either by email or any other method described in this <u>Section 6(h)</u> (excluding ***"out of office"*** or other automated replies). To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form 6-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Class B Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

*(Signature Page Follows)*

 

**IN WITNESS WHEREOF**, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

---

| | |
|:---|:---|
| **BRERA HOLDINGS PLC** | **BRERA HOLDINGS PLC** |
| By: | /s/ Sergio Carlo Scalpelli |
| Name: | Sergio Carlo Scalpelli |
| Title: | Chief Executive Officer |

---

[SIGNATURE PAGE OF REPRESENTATIVE WARRANT]

**EXHIBIT A**

**NOTICE OF EXERCISE**

TO: Brera Holdings PLC

&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 undersigned hereby elects to purchase ________________ Warrant Shares of the Company pursuant
 to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
 of the exercise price in full, together with all applicable transfer taxes, if any.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Payment
 shall take the form of in lawful money of the United States.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Please
 issue said Warrant Shares in the name of the undersigned or in such other name as is specified
 below:

---

| |
|:---|
| &nbsp;&nbsp;*Name(s):* |
|  |
| &nbsp;&nbsp;*Account Number for Delivery of Warrant Shares:* |

---

&nbsp;&nbsp;&nbsp;&nbsp;(4) <u>Accredited Investor</u>. The undersigned is an  ***"accredited investor"*** as defined
 in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name: __________________________________________________________________

Signature: __________________________________________________________________

Date: __________________________________________________________________

***<u>If Warrant Shares are to be Held Jointly:</u>***

Name: __________________________________________________________________

Signature: __________________________________________________________________

Date: __________________________________________________________________

***<u>If Holder is an Entity:</u>***

 ****

Name of Investing Entity: ______________________________________________________

 

*Signature of Authorized*

 

*Signatory of Investing Entity*: ______________________________________________________

Name of Authorized Signatory: ____________________________________________________

Title of Authorized Signatory: _____________________________________________________

Date: ________________________________________________________________________

**EXHIBIT B**

**ASSIGNMENT FORM**

 

*(To assign the foregoing Warrant, execute this form and supply the required information.)<br> (Do not use this form to exercise the Warrant to purchase shares.)*

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to:

**<u>If Warrant is Held by an Individual:</u>**

---

| | |
|:---|:---|
| *Name:* | |
|  | (Please Print) |
| *Signature:* | |
| *Dated:* | |
| *Address:* | |
| *Phone Number:* | |
| *Email Address:* | |

---

**<u>If Warrant is Held Jointly:</u>**

---

| | |
|:---|:---|
| *Name:* | |
|  | (Please Print) |
| *Signature:* | |
| *Dated:* | |
| *Address:* | |
| *Phone Number:* | |
| *Email Address:* | |

---

**<u>If Holder is an Entity:</u>**

---

| | |
|:---|:---|
| <br> *Name of Entity:* | |
| *Authorized Signature Name:* | |
|  | (Please Print) |
| *Authorized Signatory's Signature:* | |
| *Title:* | |
| *Date:* | |
| *Address:* | |
| *Phone Number:* | |
| *Email Address:* | |

---

## Exhibit 99.1

**Exhibit 99.1**

**Brera Holdings PLC Announces Pricing of Initial Public Offering**

**IPO Shares to Commence Trading Today on Nasdaq Under Ticker Symbol "BREA"**

***NEW YORK, DUBLIN and MILAN – (GlobeNewsWire) – January 27, 2023*** – Brera Holdings PLC ("Brera Holdings" or the "Company") today announced the pricing of its initial public offering of 1,500,000 Class B Ordinary Shares at a price to the public of $5.00 per share for a total of $7,500,000 of gross proceeds to the Company (the "Offering"), before deducting underwriting discounts, commissions and other Offering expenses. In addition, Brera Holdings has granted the underwriters a 45-day option to purchase up to an additional 225,000 Class B Ordinary Shares at the public offering price of $5.00 per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

The shares are expected to begin trading on The Nasdaq Capital Market today under the ticker symbol "BREA." The Offering is expected to close on January 31, 2023, subject to the satisfaction of customary closing conditions.

Revere Securities, LLC is acting as the underwriter for the Offering.

A registration statement on Form F-1, as amended (File No. 333-268187) relating to these securities was filed with the Securities and Exchange Commission ("SEC") and was declared effective on January 26, 2023. The Offering is being made only by means of a prospectus. A copy of the final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. A copy of the final prospectus relating to the Offering may be obtained, when available from Revere Securities, LLC by way of emailing requests to contact@reveresecurities.com; by calling +1 212 688 2350; or by request by standard mail to Revere Securities, LLC, Attention: Equity Capital Markets, 650 5<sup>th</sup> Ave, New York, NY 10019 USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

**About Brera Holdings PLC**

Brera Holdings PLC is an Irish holding company focused on expanding social impact football (American soccer) by developing a global portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services. The Company seeks to build on the legacy and brand of Brera FC, the first football club that was acquired by the Company. Brera FC, known as "The Third Team of Milan," is an amateur football association which has been building an alternative football legacy since its founding in 2000. The Company is focused on bottom-up value creation from sports clubs and talent outside mainstream markets, innovation-powered business growth, and socially-impactful outcomes. See www.breraholdings.com.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

**CONTACT INFORMATION:**

**<u>FOR MEDIA AND INVESTOR RELATIONS</u>**

***Outside Italy:***

Daniel McClory, Executive Chairman

Brera Holdings PLC

dan@breraholdings.com

***In Italy:***

Sergio Scalpelli, CEO

Brera Holdings PLC

sergio@breraholdings.com

## Exhibit 99.2

**Exhibit 99.2**

**Brera Holdings PLC Announces International Expansion Strategy**

**BREA Acquisition Targets in Smaller European Markets Could Earn Football Competition Prizes from $3 Million to $15 Million**

***NEW YORK, DUBLIN and MILAN – (Globe News Wire) – January 30, 2023*** – Following its Nasdaq IPO last Friday, Brera Holdings PLC ("Brera Holdings" or the "Company" Nasdaq: BREA) today announced its international strategy to simultaneously pursue expansion and licensing of the Brera FC brand in Eastern Europe, Africa, and South America, through the potential acquisition and, where appropriate, renaming of football teams with the objective of enhancing the players on these teams to place them on the professional transfer market and obtain prizes related to participation rights in UEFA..

Brera Holdings CEO Sergio Scalpelli commented: "We are currently negotiating confidential deals for top division clubs in various European countries (starting from North Macedonia), while exploring opportunities in Africa (mainly), South America and other non-European countries.The choice of countries is based upon an in-depth analysis of the football, regulatory and economic parameters that are key to our business model."

***There is a Sizeable Market for European Football Competition Prizes***. In the European countries in which Brera Holdings intends to operate, the Company intends to pursue the UEFA (Union of European Football Associations, the governing body of European football and the umbrella organization for 55 national associations) competitions market with at least three top-division teams. There are three UEFA competitions: The Champions League, or the CL, the Europa League, or the EL, and the Europa Conference League, or the Conference. A base participation prize is awarded to each of the 32 clubs that are admitted to the "group stage" of each UEFA competition.

For the 2021-2022 season, the base participation prize for each club was €15.64 million for the CL, €3.63 million for the EL and €2.94 million for the Conference. Each competition has different rules for how a club may take one of the 32 places in the competition's group stage, but generally they are admitted either automatically based on UEFA's access criteria or gain admission through qualifiers. For the CL, 26 clubs are automatically admitted to the group stage based on UEFA's criteria, and the remaining six places are divided between clubs that qualify by being league champions or by finishing second to fourth in their national championship.

For the EL, 12 clubs are automatically admitted based on UEFA's criteria, 10 are admitted by transfer from the CL by losing either of the CL's play-off or third qualifying rounds, and 10 are winners of the EL play-off round. For the Conference, 10 are admitted after losing the EL play-off round, and 22 are admitted after winning the Conference play-off round. Clubs from smaller European countries, including the Eastern European countries where Brera Holdings is exploring club acquisition opportunities, generally cannot gain automatic admission to the CL or EL due to the effect of certain coefficients that the UEFA uses to form the automatic access lists for these competitions, but they can potentially reach the group stage through the CL, EL or Conference qualifiers.

In addition, participants in certain competition qualifiers can also receive participation prizes without reaching a competition's group stage, ranging from €250,000 in the case of elimination in the first round of the Conference qualifiers, up to €5 million in the event of elimination in the last round of the CL play-off round. Commenting further, Brera Holdings CEO Scalpelli concluded: "These prizes can generate high profit margins, especially for those clubs with lower operating costs which we are targeting for acquisition. In African, South American, or other non-European markets in which we expect to acquire clubs, we instead intend to develop a vast activity for scouting purposes."

**About Brera Holdings PLC**

Brera Holdings PLC is a Nasdaq-listed (Stock Ticker: BREA) Irish holding company focused on expanding social impact football (American soccer) by developing a global portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services. The Company seeks to build on the legacy and brand of Brera FC, the first football club that was acquired by the Company. Brera FC, known as "The Third Team of Milan," is an amateur football association which has been building an alternative football legacy since its founding in 2000. The Company is focused on bottom-up value creation from sports clubs and talent outside mainstream markets, innovation-powered business growth, and socially-impactful outcomes. See www.breraholdings.com.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

**CONTACT INFORMATION:**

**<u>FOR MEDIA AND INVESTOR RELATIONS</u>**

***Outside Italy:***

Daniel McClory, Executive Chairman

Brera Holdings PLC

dan@breraholdings.com

***In Italy:***

Sergio Scalpelli, CEO

Brera Holdings PLC

sergio@breraholdings.com

## Exhibit 99.3

**Exhibit 99.3**

**Brera Holdings PLC Announces Closing of $7,500,000 Initial Public Offering**

**Shares Commenced Trading Friday on Nasdaq Under Ticker Symbol "BREA"**

***NEW YORK, DUBLIN and MILAN – (GlobeNewsWire) – January 31, 2023*** – Brera Holdings PLC ("Brera Holdings" or the "Company" Nasdaq: BREA) today announced the closing of its initial public offering of 1,500,000 Class B Ordinary Shares at a price to the public of $5.00 per share for a total of $7,500,000 of gross proceeds to the Company (the "Offering"), before deducting underwriting discounts, commissions and other Offering expenses.

Revere Securities, LLC acted as the underwriter for the Offering.

A registration statement on Form F-1, as amended (File No. 333-268187) relating to these securities was filed with the Securities and Exchange Commission ("SEC") and was declared effective on January 26, 2023. The Offering was made only by means of a prospectus. A copy of the final prospectus relating to the Offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. A copy of the final prospectus relating to the Offering may be obtained, from Revere Securities, LLC by way of emailing requests to contact@reveresecurities.com; by calling +1 212 688 2350; or by request by standard mail to Revere Securities, LLC, Attention: Equity Capital Markets, 650 5<sup>th</sup> Ave, New York, NY 10019 USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

**About Brera Holdings PLC**

Brera Holdings PLC is an Irish holding company focused on expanding social impact football (American soccer) by developing a global portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services. The Company seeks to build on the legacy and brand of Brera FC, the first football club that was acquired by the Company. Brera FC, known as "The Third Team of Milan," is an amateur football association which has been building an alternative football legacy since its founding in 2000. The Company is focused on bottom-up value creation from sports clubs and talent outside mainstream markets, innovation-powered business growth, and socially-impactful outcomes. See www.breraholdings.com.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

**CONTACT INFORMATION:**

**<u>FOR MEDIA AND INVESTOR RELATIONS</u>**

***Outside Italy:***

Daniel McClory, Executive Chairman

Brera Holdings PLC

dan@breraholdings.com

***In Italy:***

Sergio Scalpelli, CEO

Brera Holdings PLC

sergio@breraholdings.com